Subject index for 1988

Psychiatry Elsevier

Research.

26,347-374

347

Subject Index for 1988 Acetylcholine Alzheimer Dementia, brain structure, 23: I I I Activity circadian rhythms, VMA and MHPG, 23:l I9 diet, circadian rhythms, 23: I I9 Cyclic adenosine monophosphate affective disorder, alpha, receptor sensitivity, 23: I I alpha, receptor sensitivity, schizophrenia, 23: I I schizophrenia, alpha, receptor sensitivity, 23: I I Adenylate cyclase lithium, affective disorder, 24:45 phospholipase C, lithium, 24:45 Adinazolam affective disorder, amitriptyline, 23:221 melancholic subtype, amitriptyline, 23:221 Adolescence adverse family events, diagnosis, 26: I4 I affective disorder, thyroid stimulating hormone, 25:1 I communication deviance, family system distress, 26:313 Diagnostic Interview for Children and Adolescents, family events, 26: 141 thyroid stimulating hormone, affective disorder, 25: I I Adrenocorticotropic hormone affective disorder, corticotropin-releasing hormone, 24:25 affective disorder, cortisol, 24:25, 25: I affective disorder, growth hormone, 25: I affective disorder, immune response, 25: I, 25:173 affective disorder, lymphocytes, 25: I affective disorder, prolactin, 25: I bereavement, response to CRH, 25: I45 circannual rhythms, CSF, 23:257 corticotropin-releasing hormone, affective disorder, 24:25 cortisol, affective disorder, 24:25 cortisol, corticotropin-releasing hormone, 24:25 cortisol, growth hormone, 25: I cortisol, lymphocytes, 25: I cortisol, prolactin, 25: I CSF, circannual rhythms, 23:257 CSF in normals, neuropeptide levels, 23:257, 25:349 growth hormone, immunity, 25: I growth hormone, lymphocytes, 25: I growth hormone, prolactin, 25: I immune response, affective disorder, 25: I, 25: I73 lumbar puncture, stress, 25: I87 lymphocytes, affective disorder, 25: I lymphocytes, growth hormone, 25: I

Adrenocorticotropic hormone continued lymphocytes, prolactin, 25: I neuropeptide levels, CSF in normals, 231257, 251349 prolactin, affective disorder, 25: I prolactin, cortisol and growth hormone, 25: I prolactin, immunity, 25: I prolactin, lymphocytes, 25: I stress, lumbar puncture, 25: I87 Affective disorder ACTH, corticotropin-releasing hormone, 24:25 ACTH, cortisol, 2425, 25: I, 25: I73 ACTH, growth hormone, 25: I, 25: I73 ACTH, immune response, 25: I73 ACTH, immunity, 25: I ACTH, lymphocytes, 25: I ACTH, prolactin, 25: I, 25: I73 ACTH response to CRH, bereavement, 25:145 ACTH response to CRH, cortisol, 25: I45 adenylate cyclase activity, lithium, 24:45 adenylate cyclase activity, phospholipase C, 24~45 adinazolam, melancholic subtype, 23:221 adolescents, thyroid stimulating hormone, 25:1 I age, cortisol, 23: 167 age, dexamethasone suppression test, 23: 167, 24:223 age, MHPG, 24:223 age, weight, 23: 167 agitation, melancholia, 23: 167 alcoholism, evoked potentials, 25:49 alphq-adrenoceptor agonist Guanfacine, growth hormone response, 2659 alpha,-receptor sensitivity, CAMP, 23: I I alpha,-receptors, children, 23:77 aminoclonidine binding, children, 23:77 amitriptyline, melancholic subtype, 23:221 anhedonia, contingent negative variation, 23:20 I anhedonia, frontal lobe function, 23:201 anti-nuclear antibodies, neuroleptics, 24:53 antidepressant response, monoamine oxidase, 25:195 antidepressant response prediction, sex differences, 25: 195 antidepressant response prediction, tyramine sulfate excretion, 25: I95 antidepressant treatment, imipramine binding, 23:229 antidepressant treatment, social functioning, 25:213 antidepressant treatment, weight gain, 26:265 augmenting/reducing, evoked potentials, 25:9 I augmenting/reducing, laterality, 25:9l augmenting/ reducing, sleep, 25:9l

348 Affective disorder continued Affective disorder continued augmenting/reducing, sleep deprivation, 25:91 cortisol, dexamethasone suppression test, bereavement, ACTH response to CRH, 25:145 23:167, 25:19 bereavement, cortisol, 25: 145 cortisol, growth hormone, 25: I, 25: 173 bereavement, CRH stimulation, 25: 145 cortisol, immunity, 25: I, 25: I73 beta-adrenoceptors, aminoclonidine binding, cortisol, lymphocytes, 25: 1 23:77 cortisol, monoamine oxidase in platelets, 25: 19 beta-adrenoceptors, children, 23:77 cortisol, prolactin, 25: I bipolar, rapid cycling, 25: I I7 cortisol, prolactin, 25: I73 bipolar, thyroid function, 25: I I7 cortisol, REM latency, 25: 19 bipolar/unipolar difference, ventricular-brain cortisol, sleep, 25: I9 ratio, 23:277 cortisol, sleep deprivation, 23: 179 bipolar/unipolar subtype, depressive mood, cortisol, thyroid stimulating hormone, 23: I79 251243 cortisol, weight, 23: 167 bipolar/unipolar subtype, leukocyte CRH stimulation, ACTH response to CRH, concentration, 25:243 25: 145 blood pressure, hypertension, 26: I 15 CRH stimulation, bereavement, 25:145 brain binding sites, GABA, 26: II9 CRH stimulation, cortisol, 25: 145 brain binding sites, suicide, 26: I 19 delusions, melancholia, 23: 167 Brief Sexual Function Questionaire, erectile depressive mood, bipolar/unipolar subtype, dysfunction, 24:23 I 25:243 bulimia, outcome, 23:45 depressive mood, generalized anxiety disorder, caffeine, dexamethasone suppression test, 24:61 26: I83 CAMP, alpha,-receptor sensitivity, 23: I I depressive mood, leukocyte concentration, catecholamines in CSF, circannual rhythms, 25:243 25:361 depressive mood, sleep characteristics, 26: I83 children, alpha,-receptors, 23:77 depressive symptoms, dexamethasone children, aminoclonidine binding, 23:77 suppression test, 24:271 children, beta-adrenoceptors, 23:77 depressive symptoms, schizophrenia, 24:271 children, imipramine binding, 23:77 depressive symptoms, T3-T4, 24:271 children, monoamine oxidase in platelets, 24:35 dexamethasone suppression, electroconvulsive children’s symptoms, informant bias, 24:345 therapy, 24: 177 chlorophenylpiperazine, panic disorder, 25:lOl dexamethasone suppression, sleep, 24: 177 chlorophenylpiperazine, serotonin agonist, dexamethasone suppression test, age, 23: 167, 25:lOl 24~223 circadian rhythms, cortisol, 23: I79 dexamethasone suppression test, caffeine, 24:61 circadian rhythms, sleep deprivation, 23: 179 dexamethasone suppression test, depressive circadian rhythms, thyroid stimulating symptoms, 24:271 hormone, 23: I79 dexamethasone suppression test, growth circannual rhythms, catecholamines in CSF, hormone response, 26:59 dexamethasone suppression test, MHPG, 24:223 25:36 I clonidine, growth hormone, 23: 147 dexamethasone suppression test, monoamine clonidine, panic disorder, 23: I47 oxidase in platelets, 25: 19 clonidine response, growth hormone, 25:301 dexamethasone suppression test, pre/ post clonidine response, somatomedin-C, 25:301 cortisol ratio, 26:69 computed tomography, ventricular brain dexamethasone suppression test, REM latency, ratio, 23:277 25:19 contingent negative variation, anhedonia, 23:201 dexamethasone suppression test, schizophrenia, contingent negative variation, frontal lobe 24127 I function, 23:201 dexamethasone suppression test, sensitivity corticotropin-releasing hormone, ACTH and and specificity, 26:69 cortisol, 24:25 dexamethasone suppression test, sleep, 25: 19 cortisol, ACTH, 24:25, 25:1, 25: 173 dexamethasone suppression test, T3-T4, 24:27 I cortisol, ACTH response to CRH, 25:145 dexamethasone suppression test, thyroid cortisol, age, 23: 167 stimulating hormone, 241271 cortisol, bereavement, 25: 145 dexamethasone suppression test, weight, 23: 167 cortisol, circadian rhythms, 23: I79 Diagnostic Interview Schedule, computerized cortisol, corticotropin-releasing hormone, 24:25 administration, 25:335 cortisol, CRH stimulation, 25: 145 dichotic listening, laterality, 25:31

349 Affective disorder continued dietary habits, seasonal disorder, 25:323 domperidone, thyroid stimulating hormone, 25~277 duration of illness, sex differences, 23:277 duration of illness,ventricular-brain ratio, 23:277 electroconvulsive therapy, dexamethasone suppression, 24: I77 electroconvulsive therapy, sleep, 24: 177 endogenous subtype, MAO inhibitors, 23: 193 endogenous subtype, outcome, 23: I 17, 23: 193 endogenous subtype, placebo response, 23: I I7 endogenous subtype, thyroid stimulating hormone, 23: I 15 episodes of depression, suicide risk, 26:273 erectile dysfunction, Brief Sexual Function Questionaire, 24:23 I evoked potentials, alcoholism, 25:49 evoked potentials, augmenting/ reducing, 25:9l evoked potentials, laterality, 25:9l evoked potentials, sleep, 25:9 I evoked potentials, sleep deprivation, 25:91 fibroblast uptake, lithium, 24:337 fibroblast uptake, membrane potential, 24:337 fibroblast uptake, red blood cell, 24:337 fibroblast uptake, schizophrenia, 24:337 frontal lobe function, anhedonia, 23:201 frontal lobe function, contingent negative variation, 23:201 GABA, brain binding sites, 26: I I9 GABA, suicide, 26: I I9 generalized anxiety disorder, depressive mood, 26: I83 generalized anxiety disorder, sleep characteristics, 26: 183 growth hormone, ACTH, 25: I, 25: I73 growth hormone, clonidine, 23: 147, 25:301 growth hormone, cortisol, 25: I, 25: 173 growth hormone, immunity, 25: I, 25: I73 growth hormone, lymphocytes, 25: I growth hormone, panic disorder, 23: 147 growth hormone, prolactin, 24: 165, 25: I, 25: I73 growth hormone response, alpha,-adrenoceptor agonist Guanfacine, 26:59 growth hormone response, dexamethasone suppression test, 26:59 growth hormone, somatomedin-C, 25:3Ol growth hormone, tryptophan, 24: I65 hypertension, 26: I I5 hypothyroidism, lithium, 25: I I7 hypothyroidism, T3-T4, 25: I I7 imipramine binding, antidepressant treatment, 231229 imipramine binding, children, 23:77 imipramine binding, sleep, 25: I35 imipramine binding, sleep deprivation, 25: 135 imipramine, PEA, 26:239 imipramine, phenelzine, 26:239 immune response, ACTH, 25: 173

Affective disorder continued immune response, cortisol, 25: I73 immune response, growth hormone, 25: 173 immune response, prolactin, 25: 173 immunity, ACTH, 25: I immunity, cortisol, 25: I immunity, growth hormone, 25: I immunity, lymphocytes, 25: I immunity, prolactin, 25: I immunological response, lymphocytes, 25: 173 impotence, measurement methods, 26:79 impotence, nocturnal penile tumescence, 26:79 informant bias, children’s symptoms, 24:345 lactate provocation, panic attacks, 25:4l laterality, augmenting/reducing, 25:9l laterality, dichotic listening, 25:3 I laterality, evoked potentials, 25:9l laterality, sleep, 25:9l laterality, sleep deprivation, 25:9 I leukocyte concentration, bipolar/unipolar subtype, 25:243 leukocyte concentration, depressive mood, 251243 lithium, adenylate cyclase activity, 24:45 lithium, fibroblast uptake, 24:337 lithium, hypothyroidism, 25: I I7 lithium intoxication, theophylline treatment, 25:203 lithium, membrane potential, 24:337 lithium, phospholipase C, 24:45 lithium, red blood cell, 24:337 lithium, schizophrenia, 24:337 lithium, T3-T4, 25:1 17, 26:249 lymphocytes, ACTH, 25: I lymphocytes, cortisol, 25: I lymphocytes, growth hormone, 25: I lymphocytes, immunity, 25: I lymphocytes, immunological response, 25: I73 lymphocytes, prolactin, 25: I MAO inhibitors, endogenous subtype, 23: 193 MAO inhibitors, outcome, 23: 193 measurement methods, impotence, 26:79 measurement methods, nocturnal penile tumescence, 26:79 melancholia, agitation, 23: 167 melancholic subtype, adinazolam, 23:22 I melancholic subtype, amitriptyline, 23:221 membrane potential, fibroblast uptake, 24:337 membrane potential, lithium, 24:337 membrane potential, red blood cell, 24:337 membrane potential, schizophrenia, 24:337 M H PC, age, 24~223 M H PC, dexamethasone suppression test, 24:223 monoamine oxidase, antidepressant response, 25: I95 monoamine oxidase in platelets, children, 24:35 monoamine oxidase in platelets, cortisol, 25: I9 monoamine oxidase in platelets, dexamethasone suppression test, 25: I9

350 Affective

disorder continued

monoamine oxidase in platelets, REM latency, 25: 19 monoamine oxidase in platelets, sleep, 25: 19 mood response, chlorophenylpiperazine, 25: 101 mood response, panic disorder, 25:lOl mood response, serotonin agonist, 25: 101 neuroendocrine response, tryptophan treatment, 24: I65 neuroleptics, anti-nuclear antibodies, 24:53 nocturnal penile tumescence, measurement methods, 26:79 outcome, bulimia, 23:45 outcome, endogenous subtype, 23: I I7 outcome, endogenous subtype, 23: 193 outcome, MAO inhibitors, 23: 193 outcome of treatment, placebo response, 23: I 17, 261259 outcome, thyroid stimulating hormone, 26:249 panic attacks, lactate provocation, 25:4l panic disorder, chlorophenylpiperazine, 25: IO1 panic disorder, clonidine, 23: 147 panic disorder, growth hormone, 23: 147 panic disorder, mood response, 25: IO1 panic disorder, serotonin agonist, 25:lOl paroxetine binding, serotonin, 26: I I PEA, imipramine, 26:239 PEA, phenelzine, 26:239 phenelzine, imipramine, 26:239 phenelzine, PEA, 26:239 phospholipase C, lithium, 24:45 placebo response, endogenous subtype, 23:1 I7 placebo response, outcome of treatment, 26:259 prolactin, ACTH, 25:l, 25: 173 prolactin, cortisol, 25: I, 25: I73 prolactin, growth hormone, 24: 165, 25: I, 25: 173 prolactin, immune response, 25: I73 prolactin, immunity, 25: I prolactin, lymphocytes, 25: I prolactin, tryptophan, 24: I65 rapid cycling, bipolar, 25: I I7 rapid cycling, thyroid function, 25: I17 red blood cell, fibroblast uptake, 24:337 red blood cell, lithium, 24:337 red blood cell, membrane potential, 24:337 red blood cell, schizophrenia, 24:337 REM latency, cortisol, 25:19 REM latency, dexamethasone suppression test, 25:19 REM latency, monoamine oxidase in platelets, 25:19 REM latency, sleep, 25: 19 schizophrenia, dexamethasone suppression test, 24~27 I schizophrenia, thyroid stimulating hormone, 24127 I seasonal disorder, dietary habits, 25:323 sensitivity and specificity, dexamethasone suppression test, 26:69

Affective

disorder continued

serotonin agonist, chlorophenylpiperazine, 25:lOl serotonin agonist, mood response, 25: IO1 serotonin agonist, panic disorder, 25: IO1 serotonin, paroxetine binding, 26: I I sexual function, Brief Sexual Function Questionaire, 24:23 I sexual function, erectile dysfunction, 24:23 I sleep, augmenting/reducing, 25:9l sleep characteristics, depressive mood, 26: I83 sleep characteristics, generalized anxiety disorder, 26: I83 sleep, cortisol, 25: I9 sleep deprivation, augmenting/reducing, 25:9l sleep deprivation, circadian rhythms, 23: 179 sleep deprivation, cortisol, 23: 179 sleep deprivation, evoked potentials, 25:9l sleep deprivation, imipramine binding, 25: I35 sleep deprivation, imipramine binding in platelets, 25: I35 sleep deprivation, laterality, 25:9l sleep deprivation, thyroid stimulating hormone, 23: I79 sleep, dexamethasone suppression test, 24: 177, 25: I9 sleep, electroconvulsive therapy, 24: I77 sleep, evoked potentials, 25:9l sleep, imipramine binding, 25: I35 sleep, imipramine binding in platelets, 25: I35 sleep, laterality, 25:9l sleep, monoamine oxidase in platelets, 25: I9 sleep, REM latency, 25: I9 sleep, sleep deprivation, 25: I35 sleep, sleep deprivation, 25:9l social functioning, antidepressant treatment, 25:213 somatomedin-C, clonidine response, 25:301 somatomedin-C, growth hormone, 25:301 suicide, brain binding sites, 26: I I9 suicide, GABA, 26:l I9 suicide risk, episodes of depression, 26:273 T3-T4, depressive symptoms, 24:271 T3-T4, dexamethasone suppression test, 24:27 I T3-T4, hypothyroidism, 25: I I7 T3-T4, lithium, 25: I 17, 26:249 T3-T4, schizophrenia, 24:271 theophylline treatment, lithium intoxication, 25:203 thyroid function, bipolar, 25: I 17 thyroid function, lithium, 26:249 thyroid function, rapid cycling, 25: I I7 thyroid function, T3-T4, 26:249 thyroid stimulating hormone, adolescents, 25: I I thyroid stimulating hormone, circadian rhythms, 23: 179 thyroid stimulating hormone, cortisol, 23: 179 thyroid stimulating hormone, dexamethasone suppression test, 241271

351 Affective disorder continued thyroid stimulating hormone, domperidone, 251277 thyroid stimulating hormone, endogenous subtype, 23: I I5 thyroid stimulating hormone, outcome, 26:249 thyroid stimulating hormone, schizophrenia, 24127 I thyroid stimulating hormone, sleep deprivation, 23: 179 tryptophan, growth hormone, 24: 165 tryptophan, prolactin, 24: 165 tryptophan treatment, neuroendocrine response, 24: 165 tyramine sulfate excretion, antidepressant response prediction, 25: 195 tyramine sulfate excretion, sex differences, 25: I95 ventricular-brain ratio, bipolar/ unipolar difference, 23:277 ventricular-brain ratio, duration of illness, 23~277 ventricular-brain ratio, sex differences, 23:277 weight, cortisol, 23: 167 weight, dexamethasone suppression test, 23: 167 weight gain, antidepressant treatment, 26:265 Age affective disorder, cortisol, 23: 167 affective disorder, dexamethasone suppression test, 23: 167, 241223 affective disorder, MHPG, 24:223 affective disorder, thyroid stimulating hormone, 24~27 I affective disorder, ventricular-brain ratio, 23:277 affective disorder, weight, 23: 167 cholinergic agonist RS86, REM latency, 24: 137 cortisol, affective disorder, 23: 167 cortisol, dexamethasone suppression test, 23: 167 cortisol, weight, 23:167 depressive episodes, suicide risk, 26:273 dexamethasone suppression test, affective disorder, 23: 167, 24~223 dexamethasone suppression test, M H PC, 24:223 dexamethasone suppression test, schizoaffective disorder, 26:29 dexamethasone suppression test, weight, 23: 167, 26~29 growth hormone, schizophrenia, 24: 123 MHPG, affective disorder, 24:223 M H PC, dexamethasone suppression test, 24:223 monoamine oxidase in platelets, tardive dyskinesia, 25: 163 REM latency, cholinergic agonist RS86, 24: 137 schizoaffective disorder, dexamethasone suppression test, 26:29 schizoaffective disorder, weight loss, 26:29 schizophrenia, growth hormone, 24: I23 suicide risk, depressive episodes, 26:273 tardive dyskinesia, monoamine oxidase in platelets, 25: 163

Age continued thyroid stimulating hormone, affective disorder, 24127 I ventricular-brain ratio, affective disorder, 231277 weight, affective disorder, 23: 167 weight, cortisol, 23: 167 weight, dexamethasone suppression test, 23: 167, 26:29 weight loss, schizoaffective disorder, 26:29 Aggression alcoholism, evoked potentials, 25:49 Agoraphobia anxiolytics, cortisol, 24:21 I anxiolytics, depressive symptoms, 24~21 I behavioral exposure, panic attacks, 23:57 cortisol, anxiolytics, 2421 I cortisol, depressive symptoms, 24:2 I I depressive symptoms, anxiolytics, 2412 I I depressive symptoms, cortisol, 24:2 I I depressive symptoms, panic disorder, 24:2l I Diagnostic Interview Schedule, computerized administration, 23:335 electrodermal response, heart rate, 24:95 electrodermal response, imipramine, 24:95 heart rate, electrodermal response, 24:95 heart rate, imipramine, 2495 imipramine, electrodermal response, 24:95 imipramine, heart rate, 2495 panic attacks, behavioral exposure, 23:57 panic disorder, anxiolytics, 24:21 I panic disorder, cortisol, 2421 I panic disorder, depressive symptoms, 2421 I panic disorder, electrodermal response, 24:95 panic disorder, heart rate, 24:95 panic disorder, imipramine, 24:95 Alcoholism aggression, evoked potentials, 25:49 cerebral blood flow, brain regions, 24:201 cerebral blood flow, positron emission tomography, 24:201 electroencephalogram, risk, 26: 101 evoked potentials, aggression, 25:49 evoked potentials, risk, 26: I9 I panic disorder, personality disorder, 26:89 positron emission tomography, cerebral blood flow, 24:201 risk, electroencephalogram, 26: IO I risk, evoked potentials, 26: I9 I Alpha, ndrenoceptor affective disorder, CAMP, 23: I I affective disorder, children, 23:77 affective disorder, growth hormone response, 2659 affective disorder, platelets, 23:77 CAMP, affective disorder, 23: I I CAMP, platelet, 23: I I CAMP, schizophrenia, 23: I I children, affective disorder, 23:77

352 Alpha, adrenoceptor continued growth hormone response, affective disorder, 2659 schizophrenia, CAMP, 23: I I schizophrenia, platelet, 23: I I Alzheimer’s disease acetylcholine in CSF, computed tomography, 23:l I I brain structure, acetylcholine in CSF, 23: I I I computed tomography, brain structure, 23: I I I imipramine binding, monoamine oxidase in platelets, 25:3 I I Amino Acids bulimia, prolactin, 23:3 I tryptophan, affective disorder 24: I65 Aminoclonidine binding affective disorder, beta-adrenoceptors, 23:77 children, affective disorder, 23:77 Amitriptyline affective disorder, adinazolam, 23:221 affective disorder, melancholic subtype, 23:221 dose level, weight gain, 26:265 lithium, rats, 25: I8 I lithium, temperature, 25: I8 I melancholic subtype, adinazolam, 23:221 melancholic subtype, affective disorder, 23:221 temperature, lithium, 25: I8 I temperature, rats, 25: I8 I weight gain, dose level, 26:265 Anorexia nervosa beta-hydroxybutyric acid, depressive mood, 24:87 bulimia, cholinergic agonist RS-86, 26: I7 I bulimia, REM sleep induction test, 26: I71 cholinergic agonist RS-86, REM sleep induction test, 26: I7 I circadian rhythms, melatonin, 23:267 circadian rhythms, obesity, 23:267 cortisol, weight, 24:87 depressive mood, beta-hydroxybutyric acid, 24:87 depressive mood, eating attitudes, 25:277 depressive mood, norepinephrine, 24:87 depressive mood, orthostatic response, 24:87 eating attitudes, depressive mood, 25:277 free fatty acids, glucose tolerance test, 25:277 glucose tolerance test, free fatty acids, 25:277 glucose tolerance test, growth hormone, 25:277 growth hormone response, affective disorder, 26:59 insulin, glucose tolerance test, 25:277 melatonin, circadian rhythms, 23:267 melatonin, obesity, 23:267 norepinephrine, depressive mood, 24:87 norepinephrine, orthostatic response, 24:87 obesity, circadian rhythms, 23:267 orthostatic response, depressive mood, 24:87 orthostatic response, norepinephrine, 24:87 REM sleep induction test, bulimia, 26: I7 I

Anorexia nervosa continued REM sleep induction test, cholinergic agonist RS-86, 26: I7 I T3, cortisol, 24:87 weight, cortisol, 24:87 weight, T3, 24:87 Anti-histone antibodies neuroleptics, schizophrenia, 24:53 Anti-nuclear antibodies affective illness, schizophrenia, 24:53 Antidepressants ACTH response to CRH, cortisol, 25: I45 adinazolam, melancholic subtype, 23:22 I affective disorder, imipramine binding, 23:229 affective disorder, monoamine oxidase, 25: I95 affective disorder, weight gain, 26:265 amitriptyline, adinazolam, 23:221 amitriptyline, melancholic subtype, 23:22 I bulimia, outcome, 23:45 cortisol, ACTH response to CRH, 25: 145 dose and plasma levels, weight gain, 26:265 endogenous subtype, MAO inhibitors, 23: 199 GABA binding sites, post-mortem brain, 26:1 I9 imipramine binding, affective disorder, 23:229 MAO inhibitors, endogenous subtype, 23: 199 melancholic subtype, adinazolam, 23:221 melancholic subtype, amitriptyline, 23:221 monoamine oxidase, affective disorder, 25: I95 outcome, bulimia, 23:45 post-mortem brain, GABA binding sites, 26: I I9 social functioning, treatment response, 25:2 I3 weight gain, affective disorder. 26:265 weight gain, dose and plasma levels, 26:265 Anxiety cortisol, obsessive-compulsive disorder, 23: 13 I obsessive-compulsive disorder, outcome, 23: I3 I Apomorphine growth hormone, response in normals, 23:245 schizophrenia, growth hormone, 24: I23 Arecoline REM induction, normal volunteers, 24:333 sleep, T3-T4, 24:333 Arginine circannual rhythms, CSF, 23:257 Attention attention deficit disorder, reaction time, 24: I57 caffeine, normal subjects, 23:329 caffeine, word association test, 23:329 cognitive load, errors, 24: I57 word association test, caffeine, 23:329 Attention Deficit Disorder monoamine oxidase, conduct disorder, 24:35 reaction time, cognitive errors, 24: 157 Baclofen growth hormone response, schizophrenia, 26: I Beta-adrenergic receptor affective disorder, aminoclonidine binding, 23177 aminoclonidine binding, affective disorder, 23:77

353

Beta-adrenergic receptor continued children, aminoclonidine binding, 23:77 propranolol, attentional performance 23:329 Blood pressure affective disorder, hypertension, 26: II5 affective disorder, tryptophan treatment, 24:165 cerebral blood flow, generalized anxiety disorder, 23:285 cerebral blood flow, heart rate, 23:285 generalized anxiety disorder, cerebral blood flow, 23:285 heart rate, generalized anxiety disorder, 23:285 hypertension, affective disorder, 26: I I5 sodium concentration in serum, polydipsia, 26:305 tryptophan treatment, affective disorder, 24: 165 alcohol, cerebral blood flow, 24:201 alcohol, positron emission tomography, 24:201 cerebral blood flow, alcohol, 24:201 cerebral blood flow, generalized anxiety disorder, 23:285 contingent negative variation, negative symptoms, 23:201 contingent negative variation, schizophrenia, 23:20 I GABA binding sites, post-mortem brain, 26:l I9 generalized anxiety disorder, cerebral blood flow, 23:285 laterality, magnetic resonance imaging, 25:223 laterality, schizophrenia, 25223 laterality, ventricular-brain ratio, 25:223 magnetic resonance imaging, laterality, 25:223 magnetic resonance imaging, schizophrenia, 251223 magnetic resonance imaging, ventricular-brain ratio, 25:223 negative symptoms, contingent negative variation, 23:201 negative symptoms, schizophrenia, 23:201 positron emission tomography, alcohol, 24:201 positron emission tomography, cerebral blood flow, 24:201 positron emission tomography, schizophrenia, 24:1 post-mortem brain, GABA binding sites, 26: I I9 schizophrenia, contingent negative variation, 23:201 schizophrenia, laterality, 25:223 schizophrenia, magnetic resonance imaging, 25~223 schizophrenia, negative symptoms, 23:201 schizophrenia, positron emission tomography, 24: I schizophrenia, ventricular-brain ratio, 25:223 ventricular-brain ratio, laterality, 25:223 ventricular-brain ratio, magnetic resonance imaging, 25:223 ventricular-brain ratio, schizophrenia, 25:223 Blessed Dementia Scale acetylcholine in CSF, Alzheimer Dementia, 23: I I I acetylcholine in CSF, computed tomography, 23: I I I

Blessed Dementia Scale continued Alzheimer Dementia, acetylcholine in CSF, 23:1 I I Alzheimer Dementia, computed tomography, 23:1 I I computed tomography, acetylcholine in CSF, 23: I I I computed tomography, Alzheimer Dementia, 23:1 I I Bulimia affective disorder, outcome, 23:45 anorexia nervosa, cholinetgic agonist RS-86, 26:171 anorexia nervosa, REM sleep induction test, 26:171 antidepressants, outcome, 23:45 cholinergic agonist RS-86, REM sleep induction test, 26: I7 I diagnostic criteria, prevalence in Japan. 26: 163 diet, glucose, 23:3l endorphins, naltrexone, 24:195 endorphins, outcome, 24: 195 glucose, diet, 23:3l Japan, prevalence 26: I63 lactate provocation, panic disorder, 26:287 naltrexone, endorphins, 24:195 naltrexone, outcome, 24: 195 outcome, affective disorder, 23:45 outcome, antidepressants, 23:45 outcome, endorphins, 24: 195 outcome, naltrexone, 24:195 panic disorder, lactate provocation, 26:287 prevalence in Japan, diagnostic criteria, 26: 163 prolactin, tryptophan, 23:3l REM sleep induction test, cholinergic agonist RS-86, 26: I7 I tryptophan, prolactin, 23:3l Caffeine affective disorder, dexamethasone suppression test, 24:hl attention, normal subjects, 23:329 attention, word association test, 23:329 dexamethasone suppression test, affective disorder, 24:6l normal subjects, word association test, 23:329 word association test, attention, 23:329 Calcitonin circannual rhythms, neuropeptides in CSF, 231257 CSF, circannual rhythms, 23:257 monoamine metabolites, circannual rhythms, 231257 normals, CSF levels, CSF, 23:257 Calmodulin circannual rhythms, CSF, 23:257 normal values, neuropeptides, 23:257 Catecholamines affective disorder, circannual rhythms, 25:361 circadian rhythms, diet, 23: I I9 circannual rhythms, affective disorder, 23:257, 25:36 I

354 Catecholamines continued diet, circadian rhythms, 23: I I9 Cerebral blood flow alcohol, brain regions, 24:201 CO, inhalation, generalized anxiety disorder, 23:285 generalized anxiety disorder, CO, inhalation, 23:285 positron emission tomography, alcohol, 24:201 Children affective disorder, alpha, receptors, 23:77 affective disorder, aminoclonidine binding, 23:77 affective disorder, beta-adrenoceptors. 23:77 affective disorder, imipramine binding, 23:77 alpha, receptors, affective disorder, 23:77 alpha, receptors, platelets, 23:77 aminoclonidine binding, beta-adrenoceptors, 23~77 beta-adrenoceptors, affective disorder, 23:77 beta-adrenoceptors, aminoclonidine binding, 23177 communication deviance in parents, family systems, 26:3 I3 conduct disorder, dopamine-beta-hydroxylase, 24:35 conduct disorder, headache, 2559 conduct disorder, lumbar puncture, 25:59 conduct disorder, monoamine oxidase, 24:35 dopamine-beta-hydroxylase, conduct disorder, 24:35 dopamine-beta-hydroxylase, monoamine oxidase, 24:35 family systems, communication deviance in parents, 26:3 I3 headache, conduct disorder, 25:59 headache, lumbar puncture, 25:59 imipramine binding, affective disorder, 23:77 imipramine binding, platelets, 23:77 lumbar puncture, conduct disorder, 25:59 lumbar puncture, headache, 25:59 monoamine oxidase, conduct disorder, 24:35 monoamine oxidase, dopamine-betahydroxylase, 24:35 monoamine oxidase, platelet, 24:35 Chlorophenylpiperazine affective disorder, serotonin agonist, 25: 101 mood response, affective disorder, 25: IO1 panic disorder, mood response, 25: IO1 serotonin agonist, affective disorder, 25: IO I Chlorpromazine schizophrenia, post-mortem brain levels, 23: I Choline dementia, red blood cell/plasma choline ratio, 24: 109 sleep, dementia, 24: 109 Cholinergic agonist RS-86 REM latency, cholinergic agonist RS86, 24: 137 Circadian rhythms activity, diet, 23: I I9

Circadian rhythms continued activity, MHPG and VMA, 23: I I9 affective disorder, cortisol, 23: 179 affective disorder, sleep deprivation, 23: 179 affective disorder, thyroid stimulating hormone, 23: I79 anorexia nervosa, melatonin, 23:267 anorexia nervosa, obesity, 23:267 apomorphine, growth hormone, 24: 123 apomorphine, schizophrenia, 24: 123 cortisol, affective disorder, 23: I79 cortisol, sleep deprivation, 23: 179 cortisol, thyroid stimulating hormone, 23: 179 diet, activity, 23:1 I9 diet, MHPG, 23:1 I9 diet, VMA, 23:1 I9 growth hormone, apomorphine, 24: 123 growth hormone, schizophrenia, 24: 123 melatonin, anorexia nervosa, 23:267 melatonin, obesity, 23:267 MHPG, activity, 23:1 I9 MHPG, diet, 23:1 I9 obesity, anorexia nervosa, 23:267 obesity, melatonin, 23:267 schizophrenia, apomorphine, 24: 123 schizophrenia, growth hormone, 24: 123 sleep deprivation, affective disorder, 23: 179 sleep deprivation, co&sol, 23: I79 sleep deprivation, thyroid stimulating hormone, 23: 179 thyroid stimulating hormone, affective disorder, 23:179 thyroid stimulating hormone, cortisol, 23: I79 thyroid stimulating hormone, sleep deprivation, 23:179 VM A, activity, 23: I I9 VMA, diet, 23:l 19 Circannual rhythms affective disorder, catecholamines in CSF, 25:36 I calcitonin, CSF, 23:257 carbohydrate-rich foods, food intake, 25:323 catecholamines in CSF, affective disorder, 25:36l CSF, calcitonin, 23:257 CSF, neurotensin, 23:257 food intake, carbohydrate-rich foods. 25:323 growth hormone, schizophrenia, 24: 123 HIAA. neuropeotides. 23:257 HVA, neuropkpiides, 23:257 imipramine binding, platelets, 26: 157 lithium response, psychosis, 26:279 neuropeptides, 23:257 neurotensin, calcitonin, 23:257 prolactin, schizophrenia, 25: 157 schizophrenia, growth hormone, 24: 123 schizophrenia, prolactin, 25: 157 Cloimipramine T3-T4, treatment outcome, 24:271

355 Clonidine

Corticotropin releasing hormone continued

affective disorder, growth hormone, 23: 147, 2530 I affective disorder, panic disorder, 23: 147 affective disorder, somatomedin-C, 25301 growth hormone, affective disorder, 23: 147, 25:30 I growth hormone, panic disorder, 23: 147 panic disorder, affective disorder, 23: 147 panic disorder, growth hormone, 23: 147 somatomedin-C, affective disorder, 25:301 CO, inhalation generalized anxiety disorder, cerebral blood flow, 23:285

rostrocaudal gradient, normal values 25:349 Cortisol affective disorder, ACTH, 24:25, 25: I affective disorder, age, 23: 167 affective disorder, circadian rhythms, 23:179 affective disorder, corticotropin-releasing hormone, 24:25 affective disorder, dexamethasone suppression test, 23: 167 affective disorder, growth hormone, 25: I affective disorder, immunity, 25: I, 25: I73 affective disorder, lymphocytes, 25: I affective disorder, prolactin, 25: I affective disorder, sleep deprivation, 23: 179 affective disorder, thyroid stimulating hormone, 23:179 affective disorder, weight, 23: I67 age, affective disorder, 23: 167 age, dexamethasone suppression test, 23: 167 age, weight, 23: 167 agoraphobia, anxiolytics, 24:2l I agoraphobia, depressive symptoms, 24:2l I agoraphobia, panic disorder, 24:2l I anorexia nervosa, T3, 24:87 anorexia nervosa, weight, 24:87 anxiety, obsessive-compulsive disorder, 23: I3 I anxiety, outcome, 23: I3 I anxiolytics, agoraphobia, 24:2l I anxiolytics, depressive symptoms, 24:2l I anxiolytics, panic disorder, 24:2l I bereavement, ACTH response to CRH, 25: I45 catecholamines in plasma, growth hormone, 25:339 catecholamines in plasma, RS-86 muscarinic agonist, 25:339 circadian rhythms, affective disorder, 23: 179 circadian rhythms, sleep deprivation, 23: 179 circadian rhythms, thyroid stimulating hormone, 23: 179 coping behavior, dexamethasone suppression test, 23: I37 coping behavior, MM PI, 23: I37 corticotropin-releasing hormone, ACTH, 24:25 corticotropin-releasing hormone, affective disorder, 24:25 depressive symptoms, agoraphobia, 24:2l I depressive symptoms, anxiolytics, 24:21 I depressive symptoms, panic disorder, 24:2l I dexamethasone suppression test, affective disorder, 23: 167 dexamethasone suppression test, age, 23: I67 dexamethasone suppression test, coping behavior, 23: I37 dexamethasone suppression test, MMPI, 23: 137 dexamethasone suppression test, weight, 23: 167 growth hormone, ACTH, 25: I growth hormone, affective disorder, 25: I growth hormone, catecholamines in plasma, 25:339

Computed tomography

acetylcholine in CSF, Alzheimer Dementia, 23: I I I affective disorder, ventricular brain ratio, 23:277 Alzheimer Dementia, acetylcholine in CSF, 23:1 I I control samples, schizophrenia, 26:241 control samples, ventricular-brain ratio, 26:241 neuroleptic response, schizophrenia, 26:293 schizophrenia, control samples, 26:241 schizophrenia, neuroleptic response, 26:293 schizophrenia, tardive dyskinesia, 26:5 I schizophrenia, ventricular brain ratio, 24:7 I, 265 I, 26:24 I tardive dyskinesia, ventricular brain ratio, 26:5 I ventricular-brain ratio, control samples, 26:241 Concanavalin A

affective disorder, lymphocytes, 25: I natural killer cells, mitogen stimulation

25: I

Conduct disorder

affective illness, thyroid stimulating hormone, 25: I I dopamine-beta-hydroxylase, children, 24:35 headache, lumbar puncture, 25:59 lumbar puncture, children, 25:59 lumbar puncture, headache, 25:59 monoamine oxidase, children, 24:35 monoamine oxidase, platelet, 24:35 thyroid stimulating hormone, affective illness, 25: I I Contingent negative variation

brain region, schizophrenia,

negative symptoms, 23:201 negative symptoms, 23:201

Coping behavior

dexamethasone suppression test, cortisol, 23: I37 dexamethasone suppression test, denial and passivity, 23: I37 MM PI, dexamethasone suppression test, 23: I37 Corticotropin releasing hormone

ACTH response, cortisol, 25: 145 affective disorder, ACTH, 24:25 affective disorder, cortisol, 24:25 bereavement, ACTH response, 25: 145 circannual rhythms, CSF, 23:257 cortisol, affective disorder, 24:25, 25:145

356 Cortisol continued growth hormone, immunity, 25: I growth hormone, lymphocytes, 25: I growth hormone, prolactin, 25: I growth hormone, RS-86 muscarinic agonist, 25:339 immunity, ACTH, 25:1, 25: 173 immunity, affective disorder, 25: I immunity, growth hormone, 25: I immunity, lymphocytes, 25: I immunity, prolactin, 25:l lumbar puncture, stress, 25: 187 lymphocytes, ACTH, 25: I lymphocytes, affective disorder, 25: I lymphocytes, growth hormone, 25: I lymphocytes, immunity, 25: I lymphocytes, prolactin, 25:l M M PI, coping behavior, 23: I37 MM PI, dexamethasone suppression test, 23: I37 obsessive-compulsive disorder, anxiety, 23: I3 I obsessive-compulsive disorder, outcome, 23: I3 I outcome, obsessive-compulsive disorder, 23: I3 I panic disorder, agoraphobia, 24:2l I panic disorder, anxiolytics, 24:2l I panic disorder, depressive symptoms, 24:2l I prolactin, affective disorder, 25: I RS-86 muscarinic agonist, catecholamines in plasma, 25:339 RS-86 muscarinic agonist, growth hormone, 251339 sleep deprivation, affective disorder, 23: 179 sleep deprivation, circadian rhythms, 23: I79 sleep deprivation, thyroid stimulating hormone, 23:179 stress, lumbar puncture, 25: 187 T3, anorexia nervosa, 24:87 T3, weight, 24:87 thyroid stimulating hormone, affective disorder, 23:179 thyroid stimulating hormone, circadian rhythms, 23: I79 thyroid stimulating hormone, sleep deprivation, 23: 179 weight, affective disorder, 23: 167 weight, age, 23: I67 weight, anorexia nervosa, 24:87 weight, dexamethasone suppression test, 23: 167 weight, T3, 24:87 Delirium rating scale, dementia, 23:89 Dementia acetylcholine in CSF, computed tomography, 23: I I I Alzheimer’s disease, 23: I I I, 25:3 I I brain structure, acetylcholine in CSF, 23: I I I choline, red blood cell/plasma choline ratio, 24: IO9 computed tomography, brain structure, 23: I I I Delirium Rating Scale, normal values, 23:89

Dementia continued imipramine binding, monoamine oxidase in platelets, 25:3 I I normal values, Delirium Rating Scale, 23:89 red blood cell/plasma choline ratio, sleep, 24: 109 sleep, red blood cell/plasma choline ratio, 24: 109 Desipramine antidepressant action, nicotine, 25: I05 antidepressant action, rat, 25: I05 antidepressant action, temperature, 25: I05 nicotine, temperature, 25: I05 plasma level, weight gain, 26:265 temperature, antidepressant action, 25: I05 temperature, rat, 25: 105 weight gain, plasma level, 26:265 Dexamethasone suppression test affective disorder, age, 23: 167, 24:223 affective disorder, caffeine, 24:6l affective disorder, cortisol, 23: 167, 25:19 affective disorder, electroconvulsive therapy, 24: I77 affective disorder, growth hormone response, 26159 affective disorder, M H PC, 24:223 affective disorder, monoamine oxidase in platelets, 25: I9 affective disorder, pre/post cortisol ratio, 26:69 affective disorder, REM latency, 25: I9 affective disorder, schizophrenia, 24:271 affective disorder, sensitivity and specificity, 26~69 affective disorder, sleep, 24: 177, 25: I9 affective disorder, thyroid stimulating hormone, 24127 I affective disorder, weight, 23: 167 age, affective disorder, 23: 167, 24:223 age, cortisol, 23: 167 age, M H PC, 24:223 age, schizoaffective disorder, 26:29 age, weight, 23: 167, 26:29 caffeine, affective disorder, 24:6l catecholamines in plasma, muscarinic agonist RS-86, 25:339 coping behavior, cortisol, 23: 137 coping behavior, MM PI, 23: I37 cortisol, affective disorder, 23: 167, 25: I9 cortisol, age, 23: 167 cortisol, coping behavior, 23: 137 cortisol, MMPI, 23:137 cortisol, monoamine oxidase in platelets, 25: I9 cortisol, REM latency, 25: I9 cortisol response, psychomotor retardation, 25:123 cortisol response, serum levels, 25: 123 cortisol, sleep, 25: I9 cortisol, weight, 23: 167 depression ratings, duration of illness, 23:345

357 suppression test continued depression ratings, schizophrenia, 23:345 duration of illness, depression ratings, 23:345 duration of illness, schizophrenia, 23:345 electroconvulsive therapy, affective disorder, 24: I77 electroconvulsive therapy, sleep, 24: 177 growth hormone response, affective disorder, 26:59 M H PC, affective disorder, 24:223 M H PC, age, 24~223 MM PI, coping behavior, 23: 137 MMPI. cortisol. 23: I37 monoamine oxidase in platelets, affective disorder, 25: I9 monoamine oxidase in platelets, cortisol, 25: I9 monoamine oxidase in platelets, REM latency, 25:19 monoamine oxidase in platelets, sleep, 25: I9 muscarinic agonist RS-86, catecholamines in plasma, 25:339 outcome, T3-T4, 24:271 pre/post cortisol ratio, affective disorder, 26:69 pre/post cortisol ratio, sensitivity and specificity, 26:69 psychomotor retardation, cortisol response, 25: I23 psychomotor retardation, serum levels, 25: 123 REM latency, affective disorder, 25: I9 REM latency, cortisol, 25: I9 REM latency, monoamine oxidase in platelets, 25:19 schizoaffective disorder, age, 26:29 schizoaffective disorder, weightloss, 26:29 schizophrenia, affective disorder, 24:271 schizophrenia, depression ratings, 23:345 schizophrenia, duration of illness, 23:345 schizophrenia, thyroid stimulating hormone, 23:345, 24127 I sensitivity and specificity, affective disorder, 26x69 sensitivity and specificity, pre/post cortisol ratio, 26:69 serum levels, cortisol response, 25: 123 serum levels, psychomotor retardation, 25: 123 sleep, affective disorder, 24: 177, 25: I9 sleep, cortisol, 25: I9 sleep, electroconvulsive therapy, 24: I77 sleep, monoamine oxidase in platelets, 25: I9 sleep, REM latency, 25:19 T3-T4, outcome, 24:271 thyroid stimulating hormone, affective disorder, 24127 I thyroid stimulating hormone, schizophrenia, 23:345, 24127 I weight, affective disorder, 23: 167 weight, age, 23: I67 weight, cortisol, 23: I67 weight loss, age, 26:29

Dexamethasone

Dexamethasone

suppression test continued

weight loss, schizoaffective

disorder,

26:29

Diagnosis

adaptive functioning, Axis V, 24: I Adolescents, 26: I41 adolescents, adverse family events, 26: I41 adolescents, Diagnostic Interview for Children and Adolescents26: I4 I adverse family events, adolescents, 26: I4 I affective disorder, endogenous subtype, 23: 193 axis V, adaptive functioning, 24: I computerized administration, Diagnostic Interview Schedule, 23:335 diagnostic instruments, panic disorder, 26:89 diagnostic instruments, personality disorder, 26:89 Diagnostic Interview for Children and Adolescents, adolescents,26: I41 Diagnostic Interview for Children and Adolescents, adverse family Diagnostic Interview Schedule, computerized administration, 23:335 endogenous subtype, affective disorder, 23: 193 life events, adolescents, 26: I41 panic disorder, diagnostic instruments, 26:89 panic disorder, personality disorder, 26:89 personality disorder, diagnostic instruments, 26:89 personality disorder, panic disorder, 26:89 Diet

activity, circadian rhythms, 23: I I9 activitv. MHPG and VMA. 23: I I9 bulimca, glucose, 23:3 I circadian rhythms, activity, 23: I I9 glucose, bulimia, 23:3 I MHPG, activity, 23:1 I9 VMA, circadian rhythms, 23:i I9 Diagnostic Interview Schedule computerized administration, diagnostic reliability, 23:335 Domperidone

affective disorder, 25~277

thyroid

stimulating

hormone,

Dopamine

children, conduct disorder, 24:35 circannual variation, normal CSF, 23:257 conduct disorder, children, 24:35 conduct disorder, monoamine oxidase, 24:35 monoamine oxidase, children, 24:35 muscarinic agonist rs-86, neuroendocrine response, 25:339 Down’s syndrome

imipramine binding, platelet, 24:67 naloxone, prolactin, 24: I 19, 24: I21 sleep, affective disorder, 24: I77 Electroconvulsive

therapy

affective disorder, dexamethasone suppression, 24: I77 dexamethasone suppression, affective disorder, 24: I77

358 Electroconvulsive therapy continued dexamethasone suppression, sleep, 24: II7 Electrodermal response agoraphobia, heart rate, 24:95 heart rate, imipramine, 24:95 heart rate, panic disorder, 24:95 imipramine, heart rate, 24:95 imipramine, panic disorder, 24:95 neuroleptic effects, schizophrenia, 24:79 panic disorder, heart rate, 24:95 panic disorder, imipramine, 24:95 schizophrenia, neuroleptic effects, 24:79 Electroencephalography alcoholism, risk, 26: IO I Endorphins bulimia, naltrexone, 24: I95 bulimia, outcome, 24: I95 circadian rhythms, CSF in normals, 23:257 CSF in normals, circadian rhythms, 23:257 naltrexone, bulimia, 24:195 Epinephrine panic disorder, arterial levels, 25: I I I sex differences, panic disorder, 25: I I I Estradiol depressive mood, oral contraceptives, 23:23 imipramine binding, platelet, 23:23 Evoked potentials affective disorder, augmenting/reducing, 25:91 affective disorder, laterality, 25:9l affective disorder, sleep, 25:9 I affective disorder, sleep deprivation, 25:9l aggression, alcoholism, 25:49 alcoholism, aggression, 2549 alcoholism, risk, 26:191 augmenting/ reducing, affective disorder, 25:9 I laterality, affective disorder, 25:9 I laterality, augmenting/reducing, 25:9 I laterality, sleep, 25:9l laterality, sleep deprivation, 25:9 I psychotic symptoms, schizophrenia, 23:209 risk, alcoholism, 26: I9 I risk in children, schizophrenia, 26:203 schizophrenia, psychotic symptoms, 23:209 schizophrenia, risk in children, 26:203 sleep, affective disorder, 25:9l sleep, augmenting/reducing, 25:9l sleep deprivation, affective disorder, 25:9l sleep deprivation; augmenting/reducing, 25:91 sleep deprivation, laterality, 25:91 sleep, laterality, 25:9l Expressed emotion schizophrenia, speech samples, 25:261 Family parental communication deviance, child behavior, 26:3 I3 Fluphenazine magnetic resonance imaging, I9F-label, 25:73 magnetic resonance imaging, rats, 25:73

Fluphenazine continued neuroleptics, magnetic resonance imaging, 25:73 Free Fatty Acids anorexia nervosa, glucose tolerance test, 25:277 glucose tolerance test, anorexia nervosa, 25:277 growth hormone, insulin, 25:277 insulin, growth hormone, 25:277 GABA affective disorder, brain binding sites, 26: I I9 baclofen, growth hormone response in schizophrenia, 26: I brain binding sites, affective disorder, 26: I I9 brain binding sites, suicide, 26: I I9 circannual rhythms, CSF in normals, 23:257 CSF in normals, circannual rhythms, 23:257 growth hormone response in schizophrenia, baclofen, 26: I suicide, affective disorder, 26: I I9 Generalized anxiety disorder affective disorder, depressive mood, 26: 183 cerebral blood flow, CO, inhalation, 23:285 CO, inhalation, cerebral blood flow, 23:285 sleep characteristics, affective disorder, 26: 183 sleep characteristics, depressive mood, 26: I83 Geneties anxiety and personality disorders, family history interview, 26: I3 I dexamethasone suppression test, family history of affective disorder, 23:345 dexamethasone suppression test, schizophrenia, 23:345 Down’s syndrome, imipramine binding in platelet, 24:67 family history of affective disorder, dexamethasone suppression test, 23:345 family history of affective disorder, schizophrenia, 23:345 family history interview, anxiety and personality disorders, 26: I3 I Gilles de la Tourette’s syndrome, neuroleptic response, 24:25 I imipramine binding in platelet, Down’s syndrome, 24~67 interview, 26: I3 I neuroleptic response, Gilles de la Tourette’s syndrome, 24:25 I platelet serotonin uptake, twin studies, 24:263 schizophrenia, dexamethasone suppression test, 23:345 schizophrenia, family history of affective disorder, 23:345 serotonin, platelets, 24:263 twin studies, platelet serotonin uptake, 24:263 Gilles de la Tourette syndrome neuroleptic response, genetics, 24:25 I Glucose anorexia nervosa, free fatty acids, 25:277 bulimia, diet, 23:3 I free fatty acids, anorexia nervosa, 25:277

359 Growth hormone ACTH, affective disorder, 25: I ACTH, cortisol, 25: I ACTH, immunity, 25: I ACTH, lymphocytes, 25: I ACTH, prolactin, 25: I affective disorder, ACTH, 25: I affective disorder, alpha-Zadrenoceptor agonist Guanfacine, 2659 affective disorder, clonidine, 23: 147, 25:301 affective disorder, cortisol, 25: I affective disorder, dexamethasone suppression test, 26~59 affective disorder, immunity, 25: I affective disorder, lymphocytes, 25: I affective disorder, natural killer cells, 25: I73 affective disorder, panic disorder, 23: 147 affective disorder, prolactin, 24: 165, 25: I affective disorder, somatomedin-C, 25:301 affective disorder, tryptophan, 24: I65 alpha,-adrenoceptor-agonist Guanfacine, affective disorder. 26:59 anorexia nervosa, free fatty acids, 25:277 anorexia nervosa, glucose tolerance test, 25:277 anorexia nervosa, insulin, 25:277 apomorphine, response in normals, 23:245 apomorphine, schizophrenia, 24: 123 area under curve, thyroid stimulating hormone, 24:361 Baclofen, schizophrenia, 26: I catecholamines in plasma, cortisol, 25:339 catecholamines in plasma, RS-86 muscarinic agonist, 25:339 clonidine, affective disorder, 23: 147, 25:301 clonidine, panic disorder, 23: 147 clonidine response, somatomedin-C, 25:301 cortisol, ACTH, 25: I cortisol, affective disorder, 25: I cortisol, catecholamines in plasma, 25:339 cortisol, immunity, 25:l cortisol, lymphocytes, 25: I cortisol, prolactin, 25:l cortisol, RS-86 muscarinic agonist, 25:339 dexamethasone suppression test, affective disorder, 26:59 free fatty acids, anorexia nervosa, 25:277 free fatty acids, glucose tolerance test, 25:277 free fatty acids, insulin, 25:277 glucose tolerance test, anorexia nervosa, 25:277 glucose tolerance test, free fatty acids, 25:277 glucose tolerance test, insulin, 25:277 immunity, ACTH, 25: I immunity, affective disorder, 25: I immunity, cortisol, 25: I immunity, lymphocytes, 25: I immunity, prolactin, 25:l insulin, anorexia nervosa, 25:277 insulin, free fatty acids, 25:277 insulin, glucose tolerance test, 25:277 lumbar puncture, stress, 25:187

Growth hormone continued lymphocytes, ACTH, 25: I lymphocytes, affective disorder, 25: I lymphocytes, cortisol, 25: I lymphocytes, immunity, 25: I lymphocytes, prolactin, 25: I natural killer cells, affective disorder, 25: I73 panic disorder, affective disorder, 23: 147 panic disorder, clonidine, 23: 147 prolactin, ACTH, 25:l prolactin, affective disorder, 24: I65 prolactin, affective disorder, 25: I prolactin, cortisol, 25: I prolactin, immunity, 25: I prolactin, lymphocytes, 25: I prolactin, tryptophan, 24: I65 RS-86 muscarinic agonist, catecholamines in plasma, 25:339 RS-86 muscarinic agonist, cortisol, 25:339 schizophrenia, apomorphine, 24: 123 schizophrenia, Baclofen, 26: I somatomedin-C, affective disorder, 25:301 somatomedin-C, clonidine response, 25:301 stress, lumbar puncture, 25: I87 thyroid stimulating hormone, area under curve, 24361 tryptophan, affective disorder, 24: I65 Gunnfacine growth hormone response, alpha,-adrenoceptor, 26:59 Haloperidol HVA in plasma, treatment outcome, 23:39 panic disorder, agoraphobia, 2495 panic disorder, electrodermal response, 24:95 panic disorder, histrionic traits, 25:65 panic disorder, imipramine, 24:95 panic disorder, sociability, 25:65 phenelzine, posttraumatic stress disorder, 24: 149 phenelzine, scales, 24: 149 posttraumatic stress disorder, phenelzine, 24: 149 posttraumatic stress disorder, scales, 24: 149 scales, phenelzine, 24: 149 scales, posttraumatic stress disorder, 24: 149 schizophrenia, HVA in plasma, 23:39 sociability, histrionic traits, 25:65 sociability, panic disorder, 25:65 tryptophan treatment, affective disorder, 24: I65 Heart rate affective disorder, tryptophan treatment, 24: I65 agoraphobia, electrodermal response, 24:95 agoraphobia, imipramine, 24:95 blood pressure, cerebral blood flow, 23:285 blood pressure, generalized anxiety disorder, 23:285 cerebral blood flow, blood pressure, 23:285 cerebral blood flow, generalized anxiety disorder, 23:285 electrodermal response, agoraphobia, 2495 electrodermal response, imipramine, 24:95 electrodermal response, panic disorder, 24:95

360 Heart rate continued generalized anxiety disorder, blood pressure, 23:285 generalized anxiety disorder, cerebral blood flow, 23:285 histrionic traits, panic disorder, 25:65 imipramine, agoraphobia, 24:95 imipraminp, electrodermal response, 24:95 imipramine, panic disorder, 24:95 Hostility normal volunteers, HIAA, 24:187 Homovannilic acid circadian rhythms, diet, 23: I 19 circannual rhythms, CSF levels, 25:361 CSF, hostility in normal volunteers, 24: I87 CSF levels, circannual rhythms, 25:361 diet, circadian rhythms, 23: I I9 HIAA, circannual rhythms, 23:257 HIAA, neuropeptides, 23:257 hostility in normal volunteers, CSF, 24: I87 MHPG, neurolentic withdrawal. 25:233 MHPG; schizophrenia, 25:233 MHPG, tardive dyskinesia, 25:233 neuroleptic, outcome, 23:239 neuroleptic withdrawal, MHPG, 25:233 neuroleptic withdrawal, schizophrenia, 25:233 neuroleptic withdrawal, tardive dyskinesia, 25:233 neuropeptides, circannual rhythms, 23:257 neuropeptides, HIAA, 231257 schizophrenia, MHPG, 25:233 schizophrenia, neuroleptic withdrawal, 25:233 schizophrenia, outcome, 23:239 schizophrenia, tardive dyskinesia, 25:233 tardive dyskinesia, MHPG, 25:233 tardive dyskinesia, neuroleptic withdrawal, 25:233 Hydroxyindoleacetic acid circannual rhythms, CSF levels, 25:36 I circannual rhvthms. HVA. 23:257 circannual rhithms, neuropeptides, 23:257 CSF levels, circannual rhythms, 25:361 hostility, normal volunteers, 24: 187 HVA, circannual rhythms, 23:257 muscarinic agonist RS-86, neuroendocrine response, 25~339 neuropeptides, circannual rhythms, 23:257 normal volunteers, hostility, 24: 187 Hypertension affective disorder, blood pressure, 26: I I5 Hypothyroidism affective disorder, lithium, 25: 1I7 lithium, T3-T4, 25: I I7 lmipramine affective disorder, antidepressant treatment, 231229 affective disorder, children, 23:77 affective disorder, imipramine binding in platelets, 25: I35

Imipramine continued affective disorder, PEA, 26:239 affective disorder, phenelzine, 26:239 affective disorder. nlatelet bindine._. 23:77. 25: 135, 231229 _ affective disorder, sleep, 25: I35 affective disorder, sleep deprivation, 25: I35 affective disorder, weight gain, 26:265 agoraphobia, electrodermal response, 24:95 agoraphobia, heart rate, 24:95 agoraphobia, panic disorder, 2495 Alzheimer’s disease, monoamine oxidase in platelets, 25:3 I I antidepressant treatment, affective disorder, 23~229 antidepressant treatment, platelet, 23:229 children, affective disorder, 23:77 children, platelet binding, 23:77 chronic psychogenic pain, pain, 26: 149 chronic psychogenic pain, platelet binding, 26: 149 circannual rhythms, platelets, 26: 157 Down’s syndrome, platelet, 2467 electrodermal response, agoraphobia, 24:95 electrodermal response, heart rate, 24:95 electrodermal response, panic disorder, 24:95 heart rate, agoraphobia, 24195 heart rate, electrodermal response, 24195 heart rate, panic disorder, 24:95 imipramine binding in platelets, affective disorder, 25: I35 imipramine binding in platelets, sleep deprivation, 25: I35 monoamine oxidase in platelets, Alzheimer’s disease, 25:3 I I monoamine oxidase, treatment response, 25: I95 oral contraceptive, platelet, 23:23 pain, chronic psychogenic pain, 26: 149 pain, platelets, 26: 149 panic disorder, agoraphobia, 24:95 panic disorder, electrodermal response, 24:95 panic disorder, heart rate, 24:95 PEA, affective disorder, 26:239 PEA, phenelzine, 26:239 phenelzine, affective disorder, 26:239 phenelzine, PEA, 26~239 platelet, affective disorder, 23:229 platelet, antidepressant treatment, 23:229 platelet, Down’s syndrome, 2467 platelet, oral contraceptive, 23:23 platelets, affective disorder, 23:77 platelets, affective disorder, 25: I35 platelets, children, 23:77 platelets, chronic psychogenic pain, 26: 149 platelets, circannual rhythms, 26: 157 platelets, imipramine binding in platelets. 25: 135 platelets, pain, 26: 149 platelets, sleep, 25: I35 platelets, sleep deprivation, 25: I35

361 lmipramine

continued sleep deprivation, affective disorder, 25: I35 sleep deprivation, imipramine binding in platelets, 25: I35 sleep deprivation, platelets, 25: I35 sleep deprivation, sleep, 25: 135 treatment of affective disorder, social functioning, 25:213 treatment response, monoamine oxidase, 25: 195 weight gain, affective disorder, 26:265

Immunity ACTH, affective disorder, 25: I ACTH, prolactin, 25:1 affective disorder, ACTH, 25: I affective disorder, cortisol, 25: I affective disorder, growth hormone, affective disorder, lymphocytes, 25: affective disorder, prolactin. 25: I cortisol, affective disorder, 25: I growth hormone, ACTH, 25: I lymphocytes, cortisol, 25: I prolactin, lymphocytes, 25: I affective disorder, lymphocytes, 25: lymphocytes, affective disorder, 25:

25: I I, 25: I73

173 I73

affective disorder, measurement methods, 26:79 nocturnal penile tumescence, measurement methods, 26179

Insulin anorexia nervosa, glucose tolerance test, 25:277 growth hormone, glucose tolerance test, 25:277 free fatty acids, growth hormone, 25:277

lsocarboxazid 23:199

Isoproterenol lactate provocation,

panic disorder,

23: I53

Lactate provocation affective disorder, panic attacks, 25:4l bulimia, panic disorder, 26:279 family history, clinical characteristics, family history, panic disorder, 25:253 isoproterenol, panic disorder, 23: 153, panic attacks, affective disorder, 25:4l panic disorder, bulimia, 26:279 panic disorder, clinical characteristics, panic disorder, family history, 25:253 panic disorder, isoproterenol, 23: 153, 26: I53 panic disorder, placebo, 23: I61 panic disorder, primate model, 23:65 placebo, panic disorder, 23: I61 primate model, panic disorder, 23:65

augmenting/reducing, sleep deprivation, 25:9l brain regions, schizophrenia, 25:223 delusions, dichotic listening, 25:3l delusions, schizophrenia, 25:3 I dichotic listening, schizophrenia, 25:3l evoked potentials, affective disorder, 25:91 evoked potentials, augmenting/reducing, 25:9l evoked potentials, sleep deprivation, 25:9l language, affective disorder, 25:3 I magnetic resonance imaging, schizophrenia, 251223 magnetic resonance imaging, ventricular-brain ratio, 251223 schizophrenia, delusions, 25:3 I schizophrenia, dichotic listening, 25:3l schizophrenia, ventricular-brain ratio, 25:223 sleep deprivation, affective disorder, 25:9l sleep deprivation, augmenting/reducing, 25:9l sleep deprivation, evoked potentials, 25:9l sleep deprivation, sleep, 25:9 I sleep, evoked potentials, 25:9l ventricular-brain ratio, schizophrenia, 25:223

Lithium

Impotence

endogenous subtype, affective disorder,

Laterality continued

25:253 26: I53

25:253 26:43,

Laterality affective disorder, augmenting/reducing, 25:9l affective disorder, evoked potentials, 25:9l affective disorder, language, 25:3 I affective disorder, sleep deprivation, 25:9l augmenting/ reducing, affective disorder, 25:9 I augmenting/reducing, evoked potentials, 25:9l

adenylate cyclase activity, affective disorder, 24:45 adenylate cyclase activity, phospholipase C, 24:45 affective disorder, adenylate cyclase activity, 24:45 affective disorder, fibroblast uptake, 24:337 affective disorder, hypothyroidism, 25: I I7 affective disorder, membrane potential, 24:337 affective duorder, phospholipase C, 24:45 affective disorder, red blood cell, 24:337 affective disorder, schizophrenia, 24:337 affective disorder, T3-T4, 25: I 17, 26:249 affective disorder, thyroid function, 26:249 amitriptyline response, temperature, 25: I8 I circannual variation, treatment response, 26:279 fibroblast uptake, affective disorder, 24:337 fibroblast uptake, membrane potential, 24:337 fibroblast uptake, red blood cell, 24:337 fibroblast uptake, schizophrenia, 24:337 hypothyroidism, affective disorder, 25: I I7 hypothyroidism, T3-T4, 25: I I7 intoxication treatment, renal clearance, 25:203 intoxication treatment, sodium bicarbonate, 25:203 intoxication treatment, theophylline infusion, 25:203 membrane potential, fibroblast uptake, 24:337 membrane potential, red blood cell, 24:337 phospholipase C, adenylate cyclase activity, 24:45 phospholipase C, affective disorder, 24:45 psychosis, circannual rhythms, 26:279 red blood cell, affective disorder, 24:337 renal clearance, intoxication treatment, 25:203

362 Lithium continued renal clearance, sodium bicarbonate, 25:203 renal clearance, theophylline infusion, 25203 schizophrenia, fibroblast uptake, 24:337 schizophrenia, membrane potential, 24:337 schizophrenia, red blood cell, 24:337 sodium bicarbonate, intoxication treatment, 25:203 T3-T4, affective disorder, 25: I 17, 26:249 temperature, amitriptyline response, 25: I8 I theophylline infusion, intoxication treatment, 25:203 thyroid function, affective disorder, 26:249 Lymphocyte ACTH, affective disorder, 25: I affective disorder, ACTH, 25: I affective disorder, cortisol, 25: I affective disorder, growth hormone, 25: I affective disorder, immunity, 25: I affective disorder, immunological response, 25:173 affective disorder, prolactin, 25: I cortisol, ACTH, 25: I growth hormone, affective disorder, 25: I growth hormone, immunity, 25: I growth hormone, prolactin, 25: I immunity, affective disorder, 25: 1 prolactin, immunity, 25: I Magnetic resonance imaging fluphenazine, rVF-label, 25:73 fluphenazine, neuroleptics, 25:73 fluphenazine, rats, 25:73 laterality, schizophrenia, 25:223 laterality, ventricular-brain ratio, 25:223 neuroleotics. r9F-label. 25:73 neuroleptics; fluphenazine, 25:73 neuroleptics, rats, 25:73 schizophrenia, ventricular-brain ratio, 25:223 ventricular-brain ratio, laterality, 25:223 Monoamine oxidase inhibitors affective disorder, endogenous subtype, 23: I93 endogenous subtype, outcome, 23: 193 Maprotiline treatment outcome, T3-T4, 24:271 Melatonin anorexia nervosa, circadian rhythms, 23:267 obesity, circadian rhythms, 23:267 Menstrual cycle circadian rhythms, HVA, 23: II9 MHPG affective disorder, age, 24:223 affective disorder, dexamethasone suppression test, 24~223 age, affective disorder, 24:223 age, dexamethasone suppression test, 24:223 children, conduct disorder, 24:35 circadian rhythms, diet, 23: I I9 circannual rhythms, CSF, 23:257 circannual rhythms, CSF levels, 25:361

MHPG continued conduct disorder, children, 24:35 CSF, circannual rhythms, 23:257 CSF, hostility in normal volunteers, 24: 187 CSF levels, circannual rhythms, 25:361 dexamethasone suppression test, affective disorder, 24:223 dexamethasone suppression test, age, 24:223 diet, circadian rhythms, 23: 1I9 hostility in normal volunteers, CSF, 24: 187 HVA, neuroleptic withdrawal, 25:233 HVA, schizophrenia, 25:233 HVA, tardive dyskinesia, 25:233 muscarinic agonist RS-86, neuroendocrine response, 25:339 neuroleptic withdrawal, schizophrenia, 25:233 neuroleptic withdrawal, tardive dyskinesia, 25:233 schizophrenia, neuroleptic withdrawal, 25:233 schizophrenia, tardive dyskinesia, 25:233 tardive dyskinesia, neuroleptic withdrawal, 25:233 tardive dyskinesia, schizophrenia, 25:233 Monoamine oxidase affective disorder, antidepressant response, 25:195 affective disorder, cortisol, 25: I9 affective disorder, dexamethasone suppression test, 25: I9 affective disorder, REM latency, 25: I9 affective disorder, sleep, 25:19 Alzheimer’s disease, imipramine binding, 25:3 I I antidepressant response, affective disorder, 25:195 children, conduct disorder, 24:35 children, dopamine-beta-hydroxylase, 24:35 conduct disorder, dopamine-beta-hydroxylase, 24135 conduct disorder, platelet, 24:35 cortisol, affective disorder, 25: I9 cortisol, dexamethasone suppression test, 25: I9 cortisol, REM latency, 25:19 cortisol, sleep, 25: I9 dexamethasone suppression test, affective disorder, 25: 19 dexamethasone suppression test, cortisol, 25: I9 dexamethasone suppression test, REM latency, 25:19 dexamethasone suppression test, sleep, 25: 19 dopamine-beta-hydroxylase, children, 24:35 dopamine-beta-hydroxylase, conduct disorder, 24~35 dopamine-beta-hydroxylase, platelet, 24:35 imipramine binding, Alzheimer’s disease, 25:3 I I isocarboxazid tratment, endogenous depression, 23:193 phenelzine, outcome, 24: 149 phenelzine, posttraumatic stress disorder, 24: 149 platelet, children, 24:35

363 Monoamine oxidase continued platelet, conduct disorder, 24:35 platelet, dopamine-beta-hydroxylase, 24:35 platelet, tardive dyskinesia, 25: 163 posttraumatic stress disorder, outcome, 24: 149 posttraumatic stress disorder, phenelzine, 24: 149 REM latency, affective disorder, 25: I9 REM latency, cortisol, 2519 REM latency, dexamethasone suppression test, 25:19 REM latency, sleep, 25:19 sleep, affective disorder, 25: I9 sleep, cortisol, 25: I9 sleep, dexamethasone suppression test, 25: I9 sleep, REM latency, 25:19 tardive dyskinesia, platelet, 25: I63 Muscarinic receptor RS-86 muscarinic agonist, neuroendocrine response, 25:339 Naloxone electroconvulsive therapy, prolactin, 24: I I9 schizophrenia, tardive dyskinesia, 26: I9 Naltrexone bulimia, endorphins, 24: I95 bulimia, outcome, 24: I95 endorphins, outcome, 24:195 Neuroleptics age, monoamine oxidase in platelets, 25: 163 age, tardive dyskinesia, 25:163 anti-histone antibodies, schizophrenia, 24:53 CT, schizophrenia, 26:293 electrodermal response, schizophrenia, 24:79 fluphenazine, r9F-label, 25:73 fluphenazine, magnetic resonance imaging, 25173 fluphenazine, rats, 25:73 Gilles de la Tourette’s syndrome, genetics, 24:25 I HVA, outcome, 23:239 HVA, schizophrenia, 23:239, 25:233 HVA, tardive dyskinesia, 25:233 magnetic resonance imaging, r9F labels, 25:73 magnetic resonance imaging, fluphenazine, 25173 magnetic resonance imaging, rats, 25:73 M H PC, schizophrenia, 25:233 M H PC, tardive dyskinesia, 25:233 monoamine oxidase in platelets, age, 25: 163 monoamine oxidase in platelets, tardive dyskinesia, 25: 163 outcome, HVA, 23:239 outcome, schizophrenia, 23:239 positron emission tomography, schizophrenia, 24: I post-mortem brain, schizophrenia, 23: I prolactin, thyroid stimulating hormone, 24: I I7 schizophrenia, anti-histone antibodies, 24:53 schizophrenia, CT, 26:293 schizophrenia, electrodermal response, 24:79

Neuroleptics continued schizophrenia, HVA, 23:239, 25:233 schizophrenia, MHPG, 25:233 schizophrenia, outcome, 23:239 schizophrenia, positron emission tomography, 24: I schizophrenia, post-mortem brain, 23: I schizophrenia, tardive dyskinesia, 25:233 T3-T4, thyroid stimulating hormone, 24:271 tardive dyskinesia, age, 25:163 tardive dyskinesia, HVA, 25:233 tardive dyskinesia, MHPG, 25:233 tardive dyskinesia, monoamine oxidase in platelets, 25: 163 tardive dyskinesia, schizophrenia, 25:233 thyroid stimulating hormone, prolactin, 24: I I7 thyroid stimulating hormone, T3-T4, 24:271 Neuropeptides adrenocorticotropic hormone, circannual rhythms in normals, 23:257 affective disorder, clonidine response, 25301 alpha-melanocyte stimulating hormone, circannual rhythms in normals, 23:257 arginine vasopressin, normal CSF, 23:257 beta-endorphin, normal CSF, 23:257 beta-lipotropin, normal CSF, 23:257 calcitonin, normal CSF, 23:257 calmodulin, normal CSF, 23:257 circannual rhythms, monoamine metabolites, 23~257 corticotropin releasing factor, normal CSF, 231257 CSF in normals, rostrocaudal gradient, 25:349 growth hormone, somatomedin C, 25:301 neurotensin, normal CSF, 23:257 rostro-caudal gradient, CSF in normals, 25:349 somatomedin C, growth hormone releasing hormone, 25:30 I somatostatin, normal CSF, 23:257 substance P, normal CSF, 23:257 vasoactive intestinal peptide, normal CSF, 231257 Nicotine antidepressant action, desipramine, 25: I05 temperature, rat, 25: I05 Norepinephrine anorexia nervosa, depressive mood, 24:87 anorexia nervosa, orthostatic response, 24:87 circannual rhythms, level in CSF, 23:257 depressive mood, anorexia nervosa, 24:87 depressive mood, orthostatic response, 24:87 lumbar puncture, stress, 25: I87 muscarinic agonist RS-86, neuroendocrine response, 25:339 neuroendocrine response, muscarinic agonist RS-86, 25:339 orthostatic response, anorexia nervosa, 24:87 stress, lumbar puncture, 25: I87

364 Normal values ACTH in CSF, 231257 ACTH response, corticotropin-releasing hormone, 24:25 adenylate cyclase activity, platelets, 24:45 adrenocorticotropic hormone in CSF, 23:257 aminoclonidine binding, platelet, 23:77 apomorphine response, growth hormone, 24: I23 arecoline REM induction, T3-T4, 24:333 arginine vasopressin in CSF, 23:257 Beck Depression Inventory, 23:23 beta-endorphin in CSF, 23:257 beta-lipotropin in CSF, 23:257 calcitonin in CSF, 23:257 calmodulin in CSF, 23:257 circadian rhythms, melatonin, 23:267 circannual variation, prolactin, 25: 157 clonidine response, growth hormone, 23: 147 Comprehensive Psychopathological Rating Scale, 23:57 Compulsions Checklist, 23:57 concanavalin-A, T-cells, 25: I corticotropin-releasing hormone, ACTH response, 24:25 cortisol, free fatty acids in plasma, 25:277 cortisol, glucose tolerance test, 25:277 Delirium Rating Scale, dementia, 23:89 domperidone response, thyroid stimulating hormone, 25:277 DOPAC in CSF, 23:257 fibroblasts and red blood cells, lithium uptake, 241337 free fatty acids in plasma, glucose tolerance test, 251277 GABA agonist baclofen, growth hormone response, 26: I GABA in CSF, 23:257 glucose tolerance test, cortisol, 25:277 growth hormone, apomorphine response, 24: I23 growth hormone, clonidine response, 23: 147 growth hormone response, GABA agonist baclofen, 26: I growth hormone response to apomorphine, tolerance, 23:245 HIAA in CSF, 23:257 H IAA in CSF, hostility, 24: I87 HVA in CSF, 23:257 HVA in plasma, MHPG in plasma, 23:119 imipramine binding in platelets, 23:23, 23:77, 231229, 25: 135 immune cell function, neuroendocrine tests, 25: I insulin, cortisol, 25:277 lactate provocation, panic response, 23: I53 lithium uptake, fibroblasts and red blood cells, 24~337 melatonin, circadian rhythms, 23:267 M H PC in CSF, 23:257 M H PC in plasma, 23: I I9 monoamine metabolites in CSF, 23:257

Normal values continued monoamine oxidase in platelets, tyramine sulfate excretion, 25: I95 neuroendocrine tests, immune cell function, 25: I neuropeptides in CSF, 23:257 neurotensin in CSF, 23:257 norepinephrine in CSF, 23:257 panic response, lactate provocation, 23: I53 paroxetine binding, platelets, 26: I I phospholipase C activity, platelets, 24145 polysomnography, sleep characteristics, 26: I7 I, 26: 183, 26~327 prolactin, circannual variation, 25: I57 rT3, T3-T4, 24:27 I sleep characteristics, polysomnography, 26: I7 I, 26: 183. 26327 sleep quality, sleep variables, 26:327 somatostatin in CSF, 23:257 substance P in CSF, 23:257 T-cells, concanavalin-A, 25:l T3-T4, arecoline REM induction, 24333 T3-T4, rT3, 24:27 I thyroid stimulating hormone, domperidone response, 251277 tolerance, growth hormone response to apomorphine, 23:245 tyramine sulfate excretion, monoamine oxidase in platelets, 25: I95 vasoactive intestinal peptide in CSF, 23:257 VMA in plasma, 23: I I9 Obesity anorexia nervosa, circadian rhythms, 23:267 melatonin, anorexia nervosa, 23:267 Obsessive compulsive disorder

anxiety, cortisol, 23: I3 I cortisol, outcome, 23: I3 I panic attacks, outcome, 23:57 Oral contraceptives

imipramine

binding,

platelet,

23:23

Outcome

adaptive functioning, Psychiatric Epidemiology Research Interview, 24: I3 affective disorder, bulimia, 23:45 affective disorder, endogenous subtype, 23: 117, 23:193 affective disorder, MAO inhibitors, 23: I93 affective disorder, placebo response, 23: I 17, 261259 affective disorder, schizophrenia, 24:271 affective disorder, thyroid stimulating hormone, 24127 I, 261259 antidepressants, bulimia, 23:45 anxiety, cortisol, 23: I3 I anxiety, obsessive-compulsive disorder, 23: I3 I apomorphine, growth hormone, 24: I23 apomorphine, schizophrenia, 24: I23 bulimia, affective disorder, 23:45 bulimia, antidepressants, 23:45 bulimia, endorphins, 24: I95

365 Outcome continued bulimia, naltrexone, 24:195 cortisol, anxiety, 23: I3 I cortisol, obsessivecompulsive disorder, 23: I3 I depression level, thyroid function, 26:249 dexamethasone suppression test, neuroleptic response, 24:27 I dexamethasone suppression test, T3-T4, 24:271 endogenous subtype, affective disorder, 23: I 17, 23:193 endogenous subtype, MAO inhibitors, 23: 193 endogenous subtype, placebo response, 23: I I7 endorphins, bulimia, 24:195 endorphins, naltrexone, 24: 195 growth hormone, apomorphine, 24: I23 growth hormone, schizophrenia, 24: I23 HVA, neuroleptic, 23:239 HVA, schizophrenia, 23:239 isocarboxazid, endogenous subtype, 23: 193 MAO inhibitors, affective disorder, 23: 193 monoamine oxidase inhibitor, phenelzine, 24149 monoamine oxidase inhibitor, posttraumatic stress disorder, 24: 149 naltrexone, bulimia, 24195 naltrexone, endorphins, 24: 195 neuroleptic, HVA, 23:239 neuroleptic response, dexamethasone suppression test, 24:271 neuroleptic response, T3-T4, 24:27 I neuroleptic, schizophrenia, 23:239 obsessive-compulsive disorder, anxiety, 23: I3 I obsessive-compulsive disorder, cortisol, 23: I3 I obsessive-compulsive disorder, panic attacks, 23157 panic attacks, obsessive-compulsive disorder, 23157 phenelzine, monoamine oxidase inhibitor, 24149 phenelzine, posttraumatic stress disorder, 24: 149 placebo response, affective disorder, 23: I I7 26:259 placebo response, endogenous subtype, 23: I I7 posttraumatic stress disorder, phenelzine, 24: 149 Psychiatric Epidemiology Research Interview, adaptive functioning, 24: I3 schizophrenia, affective disorder, 24:271 schizophrenia, apomorphine, 24: 123 schizophrenia, growth hormone, 24: I23 schizophrenia, HVA, 23:239 schizophrenia, neuroleptic, 23:239 schizophrenia, thyroid stimulating hormone, 241271 T3-T4, dexamethasone suppression test, 24:27 I T3-T4, neuroleptic response, 24:27 I thyroid function, depression level, 26:249 thyroid stimulating hormone, affective disorder, 24127 I, 26~249

Outcome continued thyroid stimulating hormone, schizophrenia, 24~27 I Pain chronic psychogenic pain, imipramine binding, 26: 149 imipramine binding, platelets, 26: 149 Panic disorder affective disorder, chlorophenylpiperazine, 25:lOi affective disorder, clonidine, 23: 147 affective disorder, growth hormone, 23: 147 affective disorder, lactate provocation, 25:4l affective disorder, mood response, 25: 101 affective disorder, serotonin agonist, 25: 101 agoraphobia, anxiolytics, 2421 I agoraphobia, cortisol, 2421 I agoraphobia, depressive symptoms, 24:2 I I agoraphobia, electrodermal response, 24:95 agoraphobia, heart rate, 2495 agoraphobia, imipramine, 24:95 animal models, anxiety, 25:8 I animal models, phenelzine, 25:8 I animal models, triazolobenzodiazepines, 25:8 I anxiety, animal models, 25:8 I anxiety, phenelzine, 25:81 anxiety, triazolobenzodiazepines, 25:81 anxiolytics, agoraphobia, 24:21 I anxiolytics, cortisol, 24:21 I anxiolytics, depressive symptoms, 24:21 I bulimia, lactate provocation, 26:287 chlorophenylpiperazine, affective disorder, 25:lOl chlorophenylpiperazine, mood response, 25:iOl chlorophenylpiperazine, serotonin agonist, 25:IOl clonidine, affective disorder, 23: 147 clonidine, growth hormone, 23: 147 computerized administration, Diagnostic Interview Schedule, 23:335 cortisol, agoraphobia, 24:21 I cortisol, anxiolytics, 24:21 I cortisol, depressive symptoms, 24:2 I I depressive symptoms, agoraphobia, 242 I I depressive symptoms, anxiolytics, 24:21 I diagnostic instruments, personality disorder, 26:89 Diagnostic Interview Schedule, computerized administration, 23:335 electrodermal response, agoraphobia, 24:95 electrodermal response, heart rate, 24:95 electrodermal response, imipramine, 24:95 epinephrine, arterial levels, 25: I I I epinephrine, sex differences, 25: I I I family history, clinical characteristics, 25:253 family history, lactate provocation, 25:253 family history method, personality disorder, 26: I3 I

366 Panic disorder continued family history method, semistructured interview, 26:131 growth hormone, affective disorder, 23: 147 growth hormone, clonidine, 23: 147 heart rate, agoraphobia, 2495 heart rate, electrodermal response, 24:95 heart rate, histrionic traits, 25:65 heart rate, sociability, 2565 histrionic traits, heart rate, 25:65 histrionic traits, sociability, 25:65 imipramine, agoraphobia, 24:95 imipramine, electrodermal response, 24:95 imipramine, heart rate, 2495 isoproterenol, lactate provocation, 23: 153, 2643 lactate provocation, affective disorder, 25:4l lactate provocation, bulimia, 26:287 lactate provocation, clinical characteristics, 25~253 lactate provocation, family history, 25:253 lactate provocation, isoproterenol, 23: I53 lactate provocation, isoproterenol, 26:43 lactate provocation, placebo, 23: I6 I lactate provocation, primate model, 23:65 mood response, affective disorder, 25: IO1 mood response, chlorophenylpiperazine, 25: IO1 mood response, serotonin agonist, 25: IO1 obsessive-compulsive disorder, outcome, 23:57 outcome, obsessive-compulsive disorder, 23:57 personality disorder, diagnostic instruments, 26:89 personality disorder, family history method, 26:131 personality disorder, semistructured interview, 261131 phenelzine, animal models, 25:8 I phenelzine, anxiety, 25:8l placebo, lactate provocation, 23: I61 primate model, lactate provocation, 23:65 semistructured interview, family history method, 26:131 serotonin agonist, chlorophenylpiperazine, 25:lOl serotonin agonist, mood response, 25: IO1 sex differences, epinephrine, 25: I I I sociability, heart rate, 25:65 thyroid stimulating hormone, vertigo, 23:349 triazolobenzodiazepines, animal models, 25:8l triazolobenzodiazepines, anxiety, 25:8 I vertigo, thyroid stimulating hormone, 23:349 Pnroxetine affective disorder, serotonin, 26: ;I Personality disorder autonomic arousal, sociability, 25:65 diagnostic instruments, 26:89 diagnostic instruments, panic disorder, 26:89 family history method, panic disorder, 26: I3 I family history method, semistructured interview, 26:131 panic disorder, diagnostic instruments, 26:89

Personality disorder continued panic disorder, family history method, 26: I3 I panic disorder, semistructured interview, 26: I3 I semistructured interview, family history method, 26:131 sociability, autonomic arousal, 25:65 Phenelzine affective disorder, imipramine, 26:239 affective disorder, PEA, 26:239 affective disorder, social functioning, 25:2 I3 animal models, panic disorder, 25:8 I animal models, triazolobenzodiazepines, 25:8 I anxiety, panic disorder, 25:8 I anxiety, triazolobenzodiazepines, 25:8 I imipramine, affective disorder, 26239 outcome, posttraumatic stress disorder, 24: 149 panic disorder, animal models, 25:8 I panic disorder, anxiety, 25:8 I panic disorder, triazolobenzodiazepines, 25:8 I PEA, affective disorder, 26:239 posttraumatic stress disorder, outcome, 24: 149 social functioning, affective disorder, 25:213 treatmeni response, monoamine oxidase, 25: I95 triazolobenzodiazepines, panic disorder, 25:8l Phenylethylamine affective disorder, phenelzine, 26:239 imipramine, affective disorder, 26:239 Phospholipase C adenylate cyclase activity, affective disorder, 24:45 affective disorder, lithium, 24:45 Placebo affective disorder, outcome of treatment, 26:259 lactate provocation, panic disorder, 23: I61 Platelet affective disorder, alpha, receptors, 23:77 affective disorder, antidepressant treatment, 231229 affective disorder, children, 23:77 affective disorder, imipramine binding, 23:77, 231229, 25: I35 affective disorder, paroxetine binding, 26: I I affective disorder, sleep deprivation, 25: I35 alpha, receptor sensitivity, CAMP, 23: I I alpha, receptor sensitivity, schizophrenia, 23: I I alpha, receptors, affective disorder, 23:77 alpha, receptors, children, 23:77 Alzheimer’s disease, monoamine oxidase, 25:3 I I antidepressant treatment, affective disorder, 231229 antidepressant treatment, imipramine binding, 231229 CAMP, alpha, receptor sensitivity, 23: I I CAMP, schizophrenia, 23: I I children, alpha, receptors, 23:77 children, conduct disorder, 24:35 children, dopamine-beta-hydroxylase, 24:35 children, imipramine binding, 23:77 children, monoamine oxidase, 24:35 circannual rhythms, imipramine binding, 26: I57

367 Platelet continued conduct disorder, dopamine-beta-hydroxylase, 2435 conduct disorder, monoamine oxidase, 24:35 dopamine-beta-hydroxyiasc, children, 24:35 dopamine-beta-hydroxyiasc, conduct disorder, 2435 Down’s syndrome, imipramine binding, 24:67 genetics, serotonin, 24263 imipramine binding, affective disorder, 23:77, 23:229, 25: I35 imipramine binding, antidepressant treatment, 23~229 imipramine binding, children, 23:77 imipramine binding, circannual rhythms, 26: I57 imipramine binding, Down’s syndrome, 24:67 imipramine binding in platelets, sleep deprivation, 25: I35 imipramine binding, oral contraceptive, 23:23 imipramine binding, sleep deprivation, 25: I35 monoamine oxidase, Alzheimer’s disease, 25:3 I I monoamine oxidase, children, 24:35 monoamine oxidase, conduct disorder, 2435 monoamine oxidase, dopamine-betahydroxylase, 24135 monoamine oxidase, tardive dyskinesia, 25: 163 oral contraceptive, imipramine binding. 23:23 paroxetine binding, affective disorder,26: II PGEI. schizophrenia. 23: I I schizophrenia, alpha-2 receptor sensitivity, 23: I I schizophrenia, CAMP, 23:l I schizophrenia, PGEI, 23: I I serotonin, genetics, 24:263 sleep deprivation, affective disorder, 25: I35 sleep deprivation, imipramine binding, 25: I35 sleep deprivation, imipramine binding in platelets, 25: I35 sleep deprivation, sleep, 25: I35 sleep, imipramine binding, 25: I35 sleep, imipramine binding in platelets, 25: I35 tardive dyskinesia, monoamine oxidase, 25: I63 Polydipsia schizophrenia, sodium concentration in serum, 26:305 sodium concentration in serum, weight, 26:305 Positron emission tomography alcohol, cerebral blood flow, 24:201 cerebral blood flow, alcohol, 24:201 metabolic rate, subcortical areas, 24: I schizophrenia, neuroleptics, 24: I Post-mortem brain schizophrenia, neuroleptics, 23: I Post-traumatic stress disorder monoamine oxidase inhibitor, outcome, 24: I49 phenelzine, outcome, 24: I49 Primate model lactate provocation, panic disorder, 23:65 Prolactin ACTH, affective disorder, 25: I affective disorder, ACTH, 25: I

Prolactin continued affective disorder, cortisol, 25: I affective disorder, growth hormone, 24: 165,25: I affective disorder, immunity, 25: I, 25: I73 affective disorder, lymphocytes, 25: I affective disorder, tryptophan, 24: I65 bulimia, tryptophan, 23:3l catecholamines in plasma, muscarinic agonist RS-86, 25:339 circannual rhythms, schizophrenia, 25: I57 cortisol, affective disorder, 25: I electroconvulsive therapy, naloxone, 24: I I9 growth hormone, affective disorder, 24: l65,25: I haloperidol response, normal volunteers, 24: I I7 haloperidol response, thyroid stimulating hormone, 24: I I7 immunity, affective disorder, 25: I, 25: I73 lumbar puncture, stress, 25: I87 lymphocytes, affective disorder, 25: I muscarinic agonist RS-86, catecholamines in plasma, 25:339 naloxone, electroconvulsive therapy, 24: I I9 normal volunteers, haloperidol response, 24: I I7 normal volunteers, thyroid stimulating hormone, 24117 schizophrenia, circannual rhythms, 25: I57 stress, lumbar puncture, 25: I87 thyroid stimulating hormone, haloperidol response, 24: I I7 thyroid stimulating hormone, normal volunteers, 24:l I7 tryptophan, affective disorder, 24: I65 tryptophan, bulimia, 23:3 I Propranolol word association test, normal subjects, 23:329 Prostaglandin El alpha,-receptor sensitivity, affective disorder, 23: I I schizophrenia, platelet, 23: I I Race tardive dyskinesia, monoamine oxidase in platelets, 25: I63 Reaction time schizophrenia, children at risk, 26:203 Red Blood cells affective disorder, fibroblast uptake, 24:337 affective disorder, lithium, 24:337 affective disorder, membrane potential, 24:337 affective disorder, schizophrenia, 24:337 choline, dementia, 24: IO9 choline, sleep, 24: 109 dementia, sleep, 24: 109 fibroblast uptake, affective disorder, 24:337 lithium, affective disorder, 24:337 lithium, fibroblast uptake, 24:337 lithium, membrane potential, 24:337 lithium, schizophrenia, 24:337 membrane potential, affective disorder, 24:337 schizophrenia, lithium, 24:337 sleep, choline, 24: 109

368 Research strategy individual differences, clinical psychopharmacology, 25: IO9 Risk alcoholism, electroencephalogram, 26: 101 alcoholism, evoked potentials, 26: I9 I attention deficits, children, 26:223 attention deficits, schizophrenia, 26:223 children, attention deficits, 26223 children, schizophrenia, 26223 depressive episodes, suicide, 26:273 electroencephalogram, alcoholism, 26: IO1 evoked potentials, alcoholism, 26: I9 I evoked potentials, schizophrenia, 26:203 schizophrenia, children, 26:223 schizophrenia, evoked potentials, 26:203 suicide, depressive episodes, 26:273 RS-86 bulimia, REM sleep induction test, 26: I7 1 Salbutamol word association test, normal subjects, 23:329 Scales Abnormal involuntary Movement Scale, naloxone treatment, 26: I9 Acute Panic Inventorv, bulimia, 26:287 Areas of Change Questionaire, family system distress, 26:3 I3 Axis V diagnosis, Psychiatric Epidemiology Research Interview, 24: I3 Beth-Rafaelsen Melancholia Scale, placebo response, 23: I I7 Beck Depression Inventory, anorexia nervosa, 25~277 Beck Depression Inventory, imipramine binding, 23~23 Blessed Dementia Rating Scale, choline, 24: 109 Brief Psychiatric Rating Scale, naloxone response, 26: I9 Brief Psychiatric Rating Scale, neuroleptic withdrawal, 25:233 Brief Psychiatric Rating Scale, neuropsychology, 26:29 Brief Psychiatric Rating Scale, positron emission tomography, 24: I Brief Sexual Function Questionaire, erectile dysfunction, 24:23 I Bulimia Questionaire, diagnosis, 26: 163 Buss-Durkee Hostility Inventory, evoked potentials, 25:49 Carroll Rating Scale for Depression, cortisol, 24:2l I Carroll Rating Scale for Depression, melancholic depression, 23:221 Clinical Global Impression, rT3, 24:27 I Comprehensive Psychopathological Rating Scale. agoraphobia, 23:57 Compulsions Checklist, agoraphobia, 23:57 Covi Anxiety Scale, antidepressant treatment, 23:22 I Delirium Rating Scale, dementia, 23:89

Scales continued Derogatis Sexual Function Inventory, affective disorder, 24:23 I Diagnostic Interview Schedule, computerized administration, 23:335 Dyadic Adjustment Scale, commmunication deviance, 26:3 I3 Eating Attitudes Test, anorexia nervosa, 25:277 Eysenck Personality Inventory, heart rate, 25:65 Gottschalk-Gleser speech samples, expressed emotion, 25:26 I Hamilton Anxiety Rating Scale, cortisol, 24:2l I Hamilton Anxiety Rating Scale, lactate provocation, 23: 153, 25:253 Hamilton Depression Rating Scale, anorexia nervosa, 24:87 Hamilton Depression Rating Scale, antidepressant treatment, 24: 149 Hamilton Depression Rating Scale, chronic psychogenic pain, 26: I49 Hamilton Depression Rating Scale, cortisol, 23~167 Hamilton Depression Rating Scale, dementia, 24: 109 Hamilton Depression Rating Scale, dexamethasone, 26:35 Hamilton Depression Rating Scale, imipramine binding, 23:229 Hamilton Depression Rating Scale, leukocyte concentration, 25:243 Hamilton Depression Rating Scale, MAO inhibitors, 23: 199 Hamilton Depression Rating Scale, M H PC, 241223 Hamilton Depression Rating Scale, phenelzine, 24149 Hamilton Depression Rating Scale, posttraumatic stress disorder, 24: 149 Hamilton Depression Rating Scale, PGE I stimulated CAMP, 23: I I Hamilton Depression Rating Scale, serum dexamethasone level, 25: I23 Hamilton Depression Rating Scale, T3-T4,24:27 I Hamilton Depression Rating Scale, thyroid function, 26:249 Hamilton Depression Rating Scale, tryptophan treatment, 24: 165 Hostility and Direction of Hostility Scale, HIAA in CSF, 24:187 Luria-Nebraska Neuropsychological Battery, positive/negative symptoms, 2629 Michigan Discriminant Index, endogenous subtype, 23: 199 Millon Clinical Multiaxial Inventory, evoked potentials, 23:209 Millon Clinical Multiaxial Inventory, personality and panic disorders, 26:89 Mini-mental state, delirium, 23:89 Minnesota Multiphasic Personality Inventory, sleep quality, 26:327

369 Scales continued

Schizoaffective

dexamethasone suppression weight loss, age, 26:29

continued brain regions, magnetic resonance imaging, 251223 brain regions, negative symptoms, 23:201 brain regions, ventricular-brain ratio, 25:223 calcium channel blocking, negative symptoms, 23:35 I calcium channel blocking, verapamil, 23:35 I Camberwell Family Interview, relapse prediction, 25:261 CAMP, alpha, receptor sensitivity, 23: I I children at risk, attention, 26:223 children at risk, continuous performance test, 261223 circannual rhythms, prolactin. 25: 157 communication deviance in parents, family systems, 26:3 I3 computed tomography, ventricular-brain ratio, 2417 I contingent negative variation, brain region, 23:20 I contingent negative variation, negative symptoms, 23:201 continuous performance test, attention, 26:223 continuous performance test, children at risk, 26~223 control samples, ventricular-brain ratio, 26:241 cortisol in CSF, 25: 187 cortisol in CSF, lumbar puncture stress, 25: I87 CT, control samples, 26:241 CT, neuroleptic response, 26:293 CT, tardive dyskinesia, 26:5 I CT, ventricular-brain ratio, 26:241 CT, ventricular brain ratio, 26:5 I Delirium Rating Scale, dementia, 23:89 delusions, dichotic listening, 25:3 I delusions, laterality, 25:3 I dementia, Delirium Rating Scale, 23:89 depressive symptoms, affective disorder, 24:271 depressive symptoms, dexamethasone suppression test, 24:271 depressive symptoms, T3-T4, 24:271 dexamethasone suppression test, affective disorder, 24:27 I dexamethasone suppression test, depressive symptoms, 24:271 dexamethasone suppression test, family history of affective disorder, 23:345 dexamethasone suppression test, genetics, 231345 dexamethasone suppression test, schizophrenia, 23:345 dexamethasone suppression test, T3-T4, 24:27l dexamethasone suppression test, thyroid stimulating hormone, 24:27 I, 24:345 dichotic listening, delusions, 25:3 I dichotic listening, laterality, 25:3 I duration of illness, thyroid stimulating hormone, 23:345

Schizophrenia

Minnesota Multiphasic Personality Inventory, dexamethasone supression test, 23: 137 Newcastle Diagnostic Scale, thyroid stimulating hormone, 23: I I5 Newcastle Scale, endogenous subtype, 23: 199 Panic Description Scale, lactate provocation, 23:153, 23:161, 26:43 Personality Diagnostic Questionaire, panic disorder, 26:89 Personality Disorders Examination, panic disorder, 25:65 Postraumatic Stress Disorder Scale, phenelzine, 24149 Present State Exam, anxiety and psychomotor retardation items, 25: I23 Psychiatric Epidemiology Research Interview, axis V diagnosis, 24: 13 Raskin Depression Scale, antidepressant treatment, 23:221 Revised Children’s Manifest Anxiety Scale, M H PC in plasma, 24:35 Sequential matching memory task, contingent negative variation, 23:201 Social Adjustment Scale, antidepressant treatment, 25:2 I3 Structured Interview for Personality Disorders, panic disorder, 26:89 Symptom Checklist-90, lactate provocation, 25:253 test, age, 26:29

Schizophrenia

ACTH in CSF, cortisol, 25: 187 affective disorder, depressive symptoms, 24:27 I affective disorder, dexamethasone suppression test, 24:27 I affective disorder, fibroblast uptake, 24:337 affective disorder, lithium, 24:337 affective disorder, membrane potential, 24:337 affective disorder, red blood cell, 24:337 affective disorder, T3-T4, 24:27 I affective disorder, thyroid stimulating hormone, 24127 I alpha, receptor sensitivity, CAMP, 23: I I anhedonia, frontal lobe function, 23:201 anti-histone antibodies, neuroleptics, 24:53 anticholinergic medication effects, skin conductance, 24:79 apomorphine, growth hormone, 23:245, 24: I23 apomorphine, outcome, 24: I23 attention, children at risk, 26:223 attention, continuous performance test, 26:223 Baclofen, growth hormone response, 26: I Battery, 26~29 brain regions, contingent negative variation, 23:20 I brain regions, laterality, 25:223

370 continued electrodermal response, neuroleptic effects, 24179 evoked potentials, psychotic symptoms, 23:209 evoked potentials, risk in children, 26:203 expressed emotion measurement, GottschalkGleser speech samples, 25:261 expressed emotion, speech samples, 25:261 family history of affective disorder, dexamethasone suppression test, 23:345 family history of affective disorder, genetics, 23:345 family history of affective disorder, schizophrenia, 23:345 family systems, communication deviance in parents, 26:3 I3 fibroblast uptake, affective disorder, 24:337 fibroblast uptake, lithium, 24:337 fibroblast uptake, membrane potential, 24:337 fibroblast uptake, red blood cell, 24:337 frontal lobe function, anhedonia, 23:201 GABA agonist baclofen, growth hormone response, 26: I genetics, dexamethasone suppression test, 23:345 genetics, family history of affective disorder, 23:345 genetics, schizophrenia, 23:345 Gottschalk-Gleser speech samples, expressed emotion measurement, 25:261 growth hormone, apomorphine, 23:245,24: I23 growth hormone in CSF, 25: I87 growth hormone in CSF, lumbar puncture stress, 25: I87 growth hormone, outcome, 24: I23 growth hormone response, GABA agonist baclofen, 26: I HVA, neuroleptic, 23:239 HVA, neuroleptic withdrawal, 25:233 HVA, outcome, 23:239 HVA, tardive dyskinesia, 25:233 laterality, brain regions, 25:223 laterality, delusions, 25:3l laterality, dichotic listening, 25:3 I laterality, magnetic resonance imaging, 25:223 laterality, ventricular-brain ratio, 25:223 lithium, affective disorder, 24:337 lithium, fibroblast uptake, 24:337 lithium, membrane potential, 24:337 lithium, red blood cell, 24:337 lumbar puncture stress, ACTH in CSF, 25: I87 lumbar puncture stress, cortisol in CSF, 25: 187 lumbar puncture stress, growth hormone in CSF, 25: I87 lumbar puncture stress, prolactin in CSF, 25: I87 Luria-Nebraska Neuropsychological Battery, neuropsychology, 26:29 Luria-Nebraska Neuropsychological Battery, positive/ negative symptoms, 26:29

Schizophrenia

continued magnetic resonance imaging, brain regions, 25~223 magnetic resonance imaging, laterality, 25:223 magnetic resonance imaging, ventricular-brain ratio, 25:223 membrane potential, affective disorder, 24:337 membrane potential, fibroblast uptake, 24:337 membrane potential, lithium, 24:337 membrane potential, red blood cell, 24:337 MHPG, HVA, 251233 MHPG, neuroleptic withdrawal, 25:233 MHPG, tardive dyskinesia, 25:233 naloxone treatment, tardive dyskinesia, 26: I9 Negative Symptoms, 23:99, 26:29 negative symptoms, brain region, 23:201 negative symptoms, calcium channel blocking, 23:35 I negative symptoms, contingent negative variation, 23:201 negative symptoms, verapamil, 23:35 I neuroleptic effects, electrodermal response, 24:79 neuroleptic, HVA, 23:239 neuroleptic, outcome, 23:239 neuroleptic response, CT, 26:293 neuroleptic withdrawal, HVA, 25:233 neuroleptic withdrawal, MHPG, 25:233 neuroleptic withdrawal, tardive dyskinesia, 251233 neuroleptics, anti-histone antibodies, 24:53 neuroleptics, positron emission tomography, 24: I neuroleptics, post-mortem brain, 23: I neuropsychology, Luria-Nebraska Neuropsychological Battery, 26:29 neuropsychology, positive/negative symptoms, 26129 outcome, apomorphine, 24: I23 outcome, growth hormone, 24: I23 outcome, HVA. 23:239 outcome, neuroleptic, 23:239 outcome, thyroid stimulating hormone, 24:271 polydipsia, sodiumconcentration in serum, 26:305 Positive and Negative Syndrome Scale, 23:99 positive/ negative symptoms, Luria-Nebraska Neuropsychological Battery, 26:29 positive/ negative symptoms, neuropsychology, 26129 positron emission tomography, neuroleptics, 24: I post-mortem brain, neuroleptics, 23: I prolactin, circannual rhythms, 25: 157 prolactin in CSF, ACTH in CSF, 25: I87 prolactin in CSF, lumbar puncture stress, 25: I87 psychotic symptoms, evoked potentials, 23:209 red blood cell, fibroblast uptake, 24:337 red blood cell, lithium, 24:337

Schizophrenia

371 continued relapse prediction, Camberwell Family Interview, 2.5:261 risk in children, evoked potentials, 26:203 Scale for the Assessment of Negative Symptoms, 23:99 schizophrenia, dexamethasone suppression test, 23:345 schizophrenia, family history of affective disorder, 23:345 schizophrenia, genetics, 23:345 skin conductance, anticholinergic medication effects, 2479 sodium concentration in serum, polydipsia, 26:305 speech samples, expressed emotion, 25:261 T3-T4, dexamethasone suppression test, 24:27 I tardive dyskinesia, CT, 2615 I tardive dyskinesia, HVA, 25:233 tardive dyskinesia, M H PC, 25:233 tardive dyskinesia, naloxone treatment, 26: 19 tardive dyskinesia, neuroleptic withdrawal, 25:233 tardive dyskinesia, ventricular brain ratio, 26:5l thyroid stimulating hormone, affective disorder, 24:27 I thyroid stimulating hormone, dexamethasone suppression test, 23:345 thyroid stimulating hormone, duration of illness, 231345 thyroid stimulating hormone, outcome, 24:271 ventricular-brain ratio, brain regions, 25:223 ventricular-brain ratio, computed tomography, 24:7l ventricular-brain ratio, control samples, 26:241 ventricular brain ratio, CT, 26:5 I, 26:241 ventricular-brain ratio, laterality, 25:223 ventricular-brain ratio, magnetic resonance imaging, 25:223 ventricular brain ratio, tardive dyskinesia, 26:5l verapamil, calcium channel blocking, 23:35l verapamil, negative symptoms, 23:35 I weight, polydipsia, 26:305 weight, sodiumconcentration in serum, 25:305 Seasonal variation (see also Circannual rhythms) carbohydrates, dietary habits, 25:323 dietary habits, carbohydrates, 25:323 Schizophrenia

Serotonin

affective disorder, paroxetine binding, 26: I I agonist chlorphenylpiperazine, panic and affective disorder, 25: IO1 bereavement with affective illness, cortisol, 25:145 cortisol, bereavement with affective illness, 25:145 epinephrine, panic disorder, 25: I I I HIAA in CSF, hostility in normal volunteers, 24: I87

continued hostility in normal volunteers, HIAA in CSF, 24: I87 lithium-induced hypothyroidism, rapid cycling, 25:l I7 monoamine oxidase, Alzheimer’s disease, 25:3 I I monoamine oxidase, tardive dyskinesia, 25: I63 monoamine oxidase, tyramine sulfate excretion, 25:195 panic disorder, epinephrine, 25: I I I panic and affective disorder, agonist chlorphenylpiperazine, 25:lOl paroxetine binding, affective disorder, 26: I I platelet uptake, twin studies, 24263 rapid cycling, lithium-induced hypothyroidism, 25:l 17 tardive dyskinesia, monoamine oxidase, 25: I63 tyramine sulfate excretion, monoamine oxidase, 25: I95 ventricular-brain ratio, affective disorder, 23:277 Sex differences affective disorder, ventricular-brain ratio, 23:277 Alzheimer’s disease, monoamine oxidase, 25:3 I I

Serotonin

Sexual function

affective disorder, Brief Sexual Function Questionaire, 24:23 I erectile dysfunction, affective disorder, 24:231 nocturnal penile tumescence, affective disorder, 2679 Sleep

affective disorder, augmenting/ reducing, 25:9l affective disorder, cortisol, 25: I9 affective disorder, dexamethasone suppression test, 24: 177, 25: I9 affective disorder, electroconvulsive therapy, 24177 affective disorder, evoked potentials, 25:9 I affective disorder, imipramine binding, 25: I35 affective disorder, laterality, 25:9 I affective disorder, monoamine oxidase in platelets, 25: I9 affective disorder, nocturnal penile tumescence, 26~79 affective disorder, REM latency, 25: I9 affective disorder, sleep deprivation, 25:9 I, 25:135 affective disorder, sleep latency, 23: 179 arecoline, REM induction, 24:333 arecoline, T3-T4, 24:333 augmenting/ reducing, affective disorder, 25:9 I augmenting/ reducing, evoked potentials, 25:9 I augmenting/ reducing, laterality, 25:9 I augmenting/ reducing, sleep deprivation, 25:9 I choline, red blood cell/plasma choline ratio, 24: IO9 cholinergic agonist, REM latency, 24: I37 cholinergic agonist RS-86, REM sleep induction test, 26: I7 I cholinergic agonist, RS86, 24: I37

372 Sleep continued cortisol, affective disorder, 25: 19 cortisol, dexamethasone suppression test, 25: 19 cortisol, monoamine oxidase in platelets, 25: 19 cortisol, REM latency, 25: 19 cortisol, sleep deprivation, 23: I79 dementia, choline, 24109 dementia, red blood cell/plasma choline ratio, 24: IO9 dexamethasone suppression, affective disorder, 24: 177, 25: I9 dexamethasone suppression, electroconvulsive therapy, 24: I77 dexamethasone suppression test, cortisol, 25: I9 dexamethasone suppression test, monoamine oxidase in platelets, 25: 19 dexamethasone suppression test, REM latency, 25:19 electroconvulsive therapy, affective disorder, 24: I77 electroconvulsive therapy, dexamethasone suppression, 24: 177 evoked potentials, affective disorder, 25:9 I evoked potentials, augmenting/ reducing, 25:9l evoked potentials, laterality, 25:9 I evoked potentials, sleep deprivation, 25:91 first night effect, quality of sleep, 26:327 imipramine binding, affective disorder, 25: I35 imipramine binding in platelets, affective disorder, 25: I35 imipramine binding in platelets, sleep deprivation, 25: I35 imipramine binding, sleep deprivation, 25: I35 laterality, affective disorder, 25:91 laterality, augmenting/reducing, 25:9l laterality, evoked potentials, 25:9l laterality, sleep deprivation, 25:9l monoamine oxidase in platelets, affective disorder, 25: I9 monoamine oxidase in platelets, cortisol, 25: I9 monoamine oxidase in platelets, dexamethasone suppression test, 25: I9 monoamine oxidase in platelets, REM latency, 25:19 nocturnal penile tumescence, affective disorder, 26179 normal volunteers, arecoline, 24:333 normal volunteers, REM induction, 24:333 normal volunteers, T3-T4, 24:333 personality traits, poor quality, 26:327 poor quality, personality traits, 26:327 quality of sleep, first night effect, 26:327 red blood cell/plasma choline ratio, dementia, 24: IO9 REM induction, arecoline, 24:333 REM induction, normal volunteers, 24:333 REM induction, T3-T4, 24:333 REM latency, affective disorder, 25:19 REM latency, cholinergic agonist, 24: 137 REM latency, cortisol, 25: I9 REM latency, dexamethasone suppression test, 25:19

Sleep continued REM latency, monoamine oxidase in platelets, 25:19 REM latency, RS86, 24: I37 REM sleep induction test, cholinergic agonist RS-86, 26: I7 I RS86, REM latency, 24: I37 sleep deprivation, affective disorder, 25:9l, 25:135 sleep deprivation, augmenting/reducing, 25:91 sleep deprivation, evoked potentials, 25:9l sleep deprivation, imipramine binding, 25: I35 sleep deprivation, laterality, 25:9l sleep latency, affective disorder, 23: I79 T3-T4, REM induction, 24:333 thyroid stimulating hormone, sleep deprivation, 23:179 Sodium polydipsia, schizophrenia, 26:305 weight, schizophrenia, 26:305 Somatomedin C affective disorder, clonidine response, 25:301 clonidine response, growth hormone, 25:301 growth hormone, growth hormone releasing hormone, 25:301 circannual rhythms, CSF, 23:257 CSF, circannual rhythms, 23:257 Speech samples schizophrenia, expressed emotion, 25:261 Statistics covariate adjustment, factorial ANOVA, 23:3 I I power, sample size, 23:30 I sample size, nomogram, 23:30 I t-tests, power analysis, 23:285 type II error, negative experiments, 23:285 Stress affective disorder, lymphocyte concentration, 25:243 children, lumbar puncture, 25:59 lumbar puncture, neuroendocrine response, 25:187 lymphocyte concentration, affective disorder, 25:243 medical student exams, schizophrenia, 24:271 neuroendocrine response, lumbar puncture, 25:187 schizophrenia, medical student exams, 24:27 I schizophrenia, T3-T4, 24:271 schizophrenia, thyroid stimulating hormone, 2427 I T3-T4, medical student exams, 24:27 I T3-T4, schizophrenia, 24:271 thyroid stimulating hormone, medical student exams, 24:27 I thyroid stimulating hormone, schizophrenia, 24:271 Substance abuse affective disorder, thyroid stimulating hormone, 25: I I Substance P circannual rhythms, CSF, 23:257 neuropeptides, normal values, 23:257

373 T-ceils affective illness, neuroendocrine measures, 25: 2s: I73 T3-T4 affective disorder, lithium, 25: I 17, 26:249 affective disorder, schizophrenia, 24:27 I affective disorder, thyroid function, 24:271, 25:117, 26:249 anorexia nervosa, cortisol, 24:87 anorexia nervosa, weight, 24:87 arecoline, normal volunteers, 24:333 arecoline, REM sleep induction, 24:333 cortisol, anorexia nervosa, 24:87 cortisol, weight, 24:87 hypothyroidism, lithium, 25:1 I7 lithium, affective disorder, 25: I 17, 26:249 lithium, hypothyroidism, 25: I 17 lithium, thyroid function, 26:249 medical student exams, schizophrenia, 24:271 medical student exams, stress, 24:271 normal volunteers, arecoline, 24:333 normal volunteers, REM induction, 24:333 normal volunteers, sleep, 24:333 REM induction, arecoline, 24:333 REM induction, normal volunteers, 24:333 REM induction, sleep, 24:333 schizophrenia, affective disorder, 24:271 schizophrenia, medical student exams, 24:271 schizophrenia, stress, 24:271 schizophrenia, thyroid stimulating hormone. 24127 I sleep, arecoline, 24:333 sleep, normal volunteers, 24:333 sleep, REM induction, 24:333 stress, medical student exams, 24:271 stress, schizophrenia, 24:271 stress, thyroid stimulating hormone, 24:271 thyroid function, affective disorder, 26:249 thyroid function, lithium. 26:249 thyroid stimulating hormone, affective disorder, 24:271 thyroid stimulating hormone, medical student exams, 24:27 I thyroid stimulating hormone, schizophrenia, 24127 I thyroid stimulating hormone, stress, 24:271 weight, anorexia nervosa, 24:87 weight, cortisol, 24:87 Tardive dyskinesia CT, schizophrenia, 26:5l HVA, neuroleptic withdrawal, 25:233 HVA, schizophrenia, 25:233 MHPG, neuroleptic withdrawal, 25:233 monoamine oxidase, platelet, 25: I63 naloxone treatment, schizophrenia, 26: I9 neuroleptic withdrawal, HVA and MHPG, 25:233 neuroleptic withdrawal, schizophrenia, 25:233 schizophrenia, CT, 26:5l schizophrenia, HVA, 25:233 schizophrenia, MHPG, 25:233

I,

Tardive dyskinesia continued schizophrenia, naloxone treatment, 26: I9 schizophrenia, neuroleptic withdrawal, 25:233 ventricular brain ratio, schizophrenia, 2651 Temperature amitriptyline, lithium, 25:181 antidepressant action, desipramine, 25: 105 desipramine, rat, 25: 105 lithium, amitriptyline, 25: I8 I nicotine, antidepressant action, 25: I05 nicotine, rat, 25: 105 Theophylline lithium intoxication,

treatment,

25:203

Thyroid stimulating hormone response adolescents, affective disorder, 25: I I adolescents, attention deficit disorder, 25: I I adolescents, substance abuse, 25: I I affective disorder, adolescents, 25: I I affective disorder, circadian rhythms, 23: 179 affective disorder, cortisol, 23: 179 affective disorder, dexamethasone suppression test, 24:271 affective disorder, domperidone, 25:277 affective disorder, endogenous subtype, 23: I I5 affective disorder, lithium, 26:249 affective disorder, outcome, 26:249 affective disorder, schizophrenia, 24:271 affective disorder, sleep deprivation, 23: I79 affective disorder, T3-T4, 26:249 attention deficit disorder, adolescents, 25: I I attention deficit disorde, substance abuse, 25: I I circadian rhythms, affective disorder, 23: I79 circadian rhythms, cortisol, 23: 179 circadian rhythms, sleep deprivation, 23: 179 cortisol, affective disorder, 23: 179 cortisol, circadian rhythms, 23: I79 cortisol, sleep deprivation, 23: I79 dexamethasone suppression test, affective disorder, 24:271 dexamethasone suppression test, schizophrenia, 23:345, 24127 I domperidone, affective disorder, 25:277 endogenous subtype, affective disorder, 23: I I5 haloperidol response, normal volunteers, 24: I I7 haloperidol response, prolactin, 24: I I7 lithium, affective disorder, 26:249 lithium, T3-T4, 26:249 medical student exams, schizophrenia, 24:27 I medical student exams, stress, 24:271 medical student exams, T3-T4, 24:27 I neuroleptics, prolactin, 24: I I7 normal volunteers, haloperidol response, 24: I I7 normal volunteers, prolactin, 24: I 17 outcome, affective disorder, 26:249 panic disorder, vertigo, 23:349 prolactin, haloperidol response, 24: I I7 prolactin. neurolentics. 24:1 I7 prolactin, normal iolunteers, 24: I I7 schizophrenia, affective disorder, 24:271

374 Thyroid stimulating hormone response continued schizophrenia, dexamethasone suppression test, 23:345, 24:271 schizophrenia, dexamethasone suppression test, 24~27 I schizophrenia, medical student exams, 24:271 schizophrenia, stress, 24271 schizophrenia, T3-T4, 24:27 I sleep deprivation, affective disorder, 23: 179 sleep deprivation, circadian rhythms, 23: 179 sleep deprivation, cortisol, 23: I79 stress, medical student exams, 24:271 stress, schizophrenia, 24:271 stress, T3-T4, 24:271 substance abuse, adolescents, 25: I I substance abuse, attention deficit disorder, 25: I I T3-T4, affective disorder, 26:249 T3-T4, lithium, 26:249 T3-T4, medical student exams, 24:271 T3-T4, schizophrenia, 24:271 T3-T4, stress, 24:27 I vertigo, panic disorder, 23:349 Triazolobenzodiazepines affective disorder, amitriptyline, 23:221 animal models, panic disorder, 25:s I anxiety, animal models, 25~8 I anxiety, phenelzine, 25:8 I melancholic subtype, amitriptyline, 23:221 panic disorder, anxiety, 25:8 I panic disorder, phenelzine, 25:8 I phenelzine, panic disorder, 25:8l Tryptophan affective disorder, growth hormone, 24: 165 bulimia, prolactin, 23:3 I growth hormone, affective disorder, 24: I65 prolactin, affective disorder, 24: 165 prolactin, bulimia, 23:3 I Tyramine affective disorder, antidepressant response prediction, 25: 195 antidepressant response prediction, sex differences, 25: 195 Vasoactive intestinal peptide circannual rhythms, CSF, 23:257 Ventricular-brain ratio affective disorder, computed tomography, 231277 control samples, CT, 26:241 control samples, schizophrenia, 261241 laterality, magnetic resonance imaging, 25:223 laterality, schizophrenia, 25:223 Ventricular-brain ratio continued magnetic resonance imaging, laterality, 25:223 magnetic resonance imaging, schizophrenia, 251223 schizophrenia, control samples, 26:241 schizophrenia, CT, 26:51, 26:241 schizophrenia, laterality, 25:223

schizophrenia, magnetic resonance imaging, 25~223 tardive dyskinesia, schizophrenia, 26:5l Verapamil negative symptoms, schizophrenia, 23:35 I schizophrenia, calcium channel blocking, 23:351 Vertigo paiic disorder, thyroid stimulating hormone, 23:349 Vanillylmandelic acid circadian rhythms, diet, 23: I 19 Weight affective disorder, age, 23: 167 affective disorder, antidepressant treatment, 26~265 affective disorder, dexamethasone suppression test, 23: I67 affective disorder, thyroid stimulating hormone, 24:27 I age, affective disorder, 23: 167 age, dexamethasone suppression test, 23: 167, 26129 age, schizoaffective disorder, 26:29 anorexia nervosa, circadian rhythms, 23:267 anorexia nervosa, cortisol, 24:87 anorexia nervosa, melatonin, 23:267 anorexia nervosa, T3, 24:87 antidepressant treatment, affective disorder, 26~265 circadian rhythms, anorexia nervosa, 23:267 circadian rhythms, melatonin, 23:267 cortisol, age, 23: 167 cortisol, anorexia nervosa, 24:87 cortisol, t3, 2487 dexamethasone suppression test, affective disorder, 23: 167 dexamethasone suppression test, age, 23: 167, 26~29 dexamethasone suppression test, schizoaffective disorder, 26:29 dietary habits, seasonal affective disorder, 25:323 growth hormone, schizophrenia, 24: 123 melatonin, anorexia nervosa, 23:267 melatonin, circadian rhythms, 23:267 polydipsia, schizophrenia, 26:305 schizoaffective disorder, age, 26:29 schizoaffective disorder, dexamethasone suppression test, 26:29 schizophrenia, growth hormone, 24: 123 schizophrenia, polydipsia, 26:305 schizophrenia, sodiumconcentration in serum, 26:305 seasonal affective disorder, dietary habits, 25:323 sodium concentration in serum, schizophrenia, 26:305 T3, anorexia nervosa, 24:87 thyroid stimulating hormone, affective disorder, 24:27 I